(51) International Patent Classification:
C07K 17/00 (2006.01)  C12P 21/06 (2006.01)

(21) International Application Number:
PCT/US2016/01517

(22) International Filing Date:
27 January 2016 (27.01.2016)

(25) Filing Language:
English

(26) Publication Language:
English

(30) Priority Data:

(71) Applicant: BRANDEIS UNIVERSITY [US/US]; 415 South Street, MS 009, Boston, Massachusetts 02453-2728 (US).

(72) Inventors: KERN, Dorothee; c/o Brandeis University, 415 South Street, MS 009, Waltham, Massachusetts 02453-2728 (US). ZORBA, Adelajda; c/o Brandeis University, 415 South Street, MS 009, Waltham, Massachusetts 02453-2728 (US).

(74) Agents: HUNTER-ENSOR, Melissa et al.; Soul Ewing LLP, Centre Square West, 1500 Market Street, 38th Floor, Philadelphia, Pennsylvania 19102-2186 (US).


Published:
— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS AND METHODS FOR MODULATING KINASE ACTIVITY

(57) Abstract: The present invention features an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, therapeutic compositions comprising this antibody mimetic, and the use of the monobody to modulate Aurora A kinase for the treatment of cancer.
COMPOSITIONS AND METHODS FOR MODULATING KINASE ACTIVITY

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims benefit of U.S. Provisional Application Serial No. 62/254,974, filed on November 13, 2015, the contents of which are incorporated herein by reference in their entirety.

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

This invention was made with government support under Grant No. DE-FG02-05ER15699 awarded by the U.S. Department of Energy and Grant Nos. GM100966-01 and GM096053 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

Deregulation of protein kinases can lead to aberrant signaling and abnormal events in cells that may contribute to the formation or growth of a cancer. An example of such a protein kinase is Aurora A kinase, an oncoprotein that is overexpressed in a multitude of cancers. As such, ways to inhibit kinases such as Aurora A kinase via small molecule drugs have been actively pursued. Typically, small molecule kinase inhibitors are developed to target the ATP binding pocket of the kinase. However, drugs developed to target the ATP binding site of a kinase are not usually specific for the particular kinase, which may lead to side effects from the drug. Thus, new methods of modulating kinase activity, particularly methods for specifically modulating activity of selected kinases in a cancer, are urgently required.

SUMMARY OF THE INVENTION

The present invention features an antibody mimetic that specifically binds to an allosteric site of Aurora A kinase, therapeutic compositions comprising this antibody mimetic, and the use of the antibody mimetic to modulate the Aurora A kinase for the treatment of cancer.
In one aspect, the present invention provides an antibody mimic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase.

In another aspect, the present invention provides a fusion polypeptide comprising a first polypeptide and a second polypeptide fused to the first polypeptide, wherein the first polypeptide is an antibody mimic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, and the second polypeptide comprises at least one of the following: (i) a fragment sufficient to mediate intracellular delivery of the antibody mimic, (ii) an epitope tag, and (iii) a detectable moiety.

In various embodiments of any one of the aspects delineated herein, the antibody mimic is a monobody. In various embodiments, the antibody mimic comprises any one of the following sequences:

AuroraA_2 (Mb2) (SEQ ID NO: 1)
SVSSVPTK LEVVAATPTS LLISWDAGFH QYEPVVYYRI TYGETGNNSP VQEFTVPGYY STATISGLKP GVDYTITVYA WYDGYSYSSP ISINYRT

AuroraA_44 (Mb44) (SEQ ID NO: 2)
SVSSVPTK LEVVAATPTS LLISWDAPAV TVDFYVITYG ETGGYSPFWQ EFEVPGSKST ATISGLKPGV DYTITYADY QYFYSPISI NYRT

AuroraA_51 (Mb51) (SEQ ID NO: 3)
SVSSVPTK LEVVAATPTS LLISWDAKPM SYEPVVYYRI TYGETGNNSP VQEFTVPGGY STATISGLKP GVDYTITVYA DMSSYYJISSP ISINYRT

AuroraA_54 (Mb54) (SEQ ID NO: 4)
SVSSVPTK LEVVAATPTS LLISWDATQTY QMYDYSYYSR ITYGETGGSNS PVQFEPFPGY YSTATISGLK PVDYITVITY AEGYSSYISSP ISINYRT

AuroraA_56 (Mb56) (SEQ ID NO: 5)
SVSSVPTK LEVVAATPTS LLISWDAMSMD WYWYDDYRYI TYGETGNNSP VQEFTVPFSY STATISGLKP GVDYTIVTYA SEDWGDYSSP ISINYRT

AuroraA_60 (Mb60) (SEQ ID NO: 6)
SVSSVPTK LEVVAATPTS LLISWDAPAV TVHYVITYG ETGGNSPVQE PTVPGSKSTA TISGLKPGVD YTIITVIAIDF WYGYSYSPII NYRT

In various embodiments of any one of the aspects delineated herein, the antibody mimic or fusion polypeptide binds to the allosteric site with affinity of at least about 1 nM, at least about 10 nM, at least about 100 nM, or at least about 1 μM. In various embodiments, the allosteric site is a PIF pocket. In some embodiments, binding of the antibody mimic or fusion polypeptide to the allosteric site alters an activity of Aurora A kinase. In some other embodiments, the antibody mimic or fusion polypeptide binding decreases kinase activity of Aurora A kinase. In still other embodiments, the antibody mimic or fusion polypeptide binding disrupts binding of TPX2 to Aurora A kinase. In some embodiments, the fragment is
a supercharged polypeptide. In some other embodiments, the supercharged polypeptide is supercharged green fluorescent protein (GFP).

In another aspect, the present invention provides an isolated polynucleotide encoding an antibody mimetic or fusion polypeptide of any one of the aspects delineated herein.

In yet another aspect, the present invention provides an expression vector comprising a polynucleotide encoding an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase. In various embodiments, the polynucleotide is the polynucleotide of any one of the aspects delineated herein. In some embodiments, the polynucleotide encodes an amino acid sequence of at least one monobody selected from the group consisting of: Mb2, Mb44, Mb51, Mb56, Mb54, and Mb60.

In still another aspect, the present invention provides a cell comprising the expression vector of any one of the aspects delineated herein. In various embodiments, the cell is a prokaryote or eukaryote.

In another aspect, the present invention provides a method of producing a polypeptide comprising an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, the method comprising (a) heterologously expressing an expression vector comprising a polynucleotide encoding the polypeptide in a host cell; (b) isolating the polypeptide from the host cell. In various embodiments, the polypeptide is the antibody mimetic or fusion polypeptide of any one of the aspects delineated herein. In some embodiments, the expression vector is the expression vector of any one of the aspects delineated herein. In some other embodiments, the host cell is the cell of any one of the aspects delineated herein.

In yet another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of an antibody mimetic, polypeptide, or polynucleotide of any one of the aspects delineated herein. In some embodiments, the composition further comprises a liposome. In some other embodiments, the composition further comprises a pharmaceutically acceptable excipient. In still other embodiments, the composition is formulated for intravenous delivery.

In another aspect, the present invention provides a method of identifying an antibody mimetic that specifically binds to an allosteric site of Aurora A kinase, the method comprising (a) contacting a candidate antibody mimetic with an Aurora A kinase having an unbound allosteric site, (b) contacting the candidate antibody mimetic with an Aurora A kinase having
a bound allosteric site or an Aurora A kinase having a mutation in the allosteric site, and (c) measuring binding of the candidate antibody mimic with Aurora A kinase in step (a) and in step (b), wherein a candidate antibody mimic having an increased binding to Aurora A kinase in step (a) relative to step (b) is identified as an antibody mimic that specifically binds to an allosteric site of Aurora A kinase. In some embodiments, the antibody mimic is a monobody. In some other embodiments, the allosteric site is a PIF pocket. In some other embodiments, the Aurora A kinase having a bound allosteric site is Aurora A kinase bound with TPX2.

In another aspect, the present invention provides a method of modulating activity of an Aurora A kinase, the method comprising contacting the Aurora A kinase with a polypeptide comprising an antibody mimic, or antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, thereby modulating the activity of the Aurora A kinase.

In yet another aspect, the present invention provides a method of inhibiting proliferation and/or reducing survival of a cell, the method comprising contacting an Aurora A kinase in the cell with a polypeptide comprising an antibody mimic, or antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, thereby inhibiting proliferation and/or reducing survival of the cell.

In still another aspect, the present invention provides a method of treating a cancer in a subject, the method comprising administering to the subject an effective amount of a composition comprising a polypeptide comprising an antibody mimic, or antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, thereby treating the cancer in the subject.

In various embodiments of any one of the aspects delineated herein, the antibody mimic is a monobody. In some embodiments, the polypeptide is the antibody mimic or fusion polypeptide of any one of the aspects delineated herein. In some other embodiments, the polypeptide is produced according to the method of any one of the aspects delineated herein. In still other embodiments, the polypeptide binds to the allosteric site with affinity of at least about 1 nM, at least about 10 nM, at least about 100 nM, or at least about 1 µM. In various embodiments, the allosteric site is a PIF pocket.

In some embodiments, binding of the polypeptide to the allosteric site alters an activity of Aurora A kinase. In various embodiments, the polypeptide binding decreases kinase activity of Aurora A kinase. In some other embodiments, the polypeptide binding
disrupts binding of TPX2 to Aurora A kinase. In still other embodiments, the polypeptide contacts Aurora A kinase in vitro or in a cell.

In various embodiments of any one of the aspects delineated herein, the polypeptide is delivered to the cell by contacting the cell with a composition comprising the polypeptide or by heterologously expressing the polypeptide in the cell. In some embodiments, the composition further comprises a liposome. In various embodiments, the cell is a cancer cell. In various embodiments of any one of the aspects delineated herein, the subject is human.

Compositions and articles defined by the invention were isolated or otherwise manufactured in connection with the examples provided below. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.

**Definitions**

Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise.

As used herein, “activity” or “biological activity” of a polypeptide refers to any biological function or any biological interaction of a polypeptide. Activity of a polypeptide may refer to the polypeptide’s enzymatic or catalytic activity (e.g., kinase activity). For example, “kinase activity” of Aurora A kinase refers to Aurora A kinase’s phosphorylation of a serine or threonine residue on a substrate polypeptide. Activity of a polypeptide may also refer to the polypeptide’s binding with another polypeptide, a polynucleotide, or other agents in a cell. For example, Aurora A kinase’s binding to TPX2 is an activity of Aurora A kinase.

The term “antibody,” as used herein, refers to an immunoglobulin molecule which specifically binds with an antigen. Methods of preparing antibodies are well known to those of ordinary skill in the science of immunology. Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources and can be immunoreactive portions of intact immunoglobulins. Antibodies are typically tetramers of immunoglobulin molecules. Tetramers may be naturally occurring or reconstructed from single chain
antibodies or antibody fragments. Antibodies also include dimers that may be naturally occurring or constructed from single chain antibodies or antibody fragments. The antibodies in the present invention may exist in a variety of forms including, for example, polyclonal antibodies, monoclonal antibodies, Fv, Fab and F(ab')2, as well as single chain antibodies (scFv), humanized antibodies, and human antibodies (Harlow et al., 1999, In: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In: Antibodies: A Laboratory Manual, Cold Spring Harbor, New York; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426).

The term “antibody fragment” refers to a portion of an intact antibody and refers to the antigenic determining variable regions of an intact antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, scFv antibodies, single-domain antibodies, such as camelid antibodies (Riechmann, 1999, Journal of Immunological Methods 231:25-38), composed of either a VL or a VH domain which exhibit sufficient affinity for the target, and multispecific antibodies formed from antibody fragments. The antibody fragment also includes a human antibody or a humanized antibody or a portion of a human antibody or a humanized antibody.

Antibodies can be made by any of the methods known in the art utilizing a polypeptide of the invention (e.g., Aurora A kinase), or immunogenic fragments thereof, as an immunogen. One method of obtaining antibodies is to immunize suitable host animals with an immunogen and to follow standard procedures for polyclonal or monoclonal antibody production. The immunogen will facilitate presentation of the immunogen on the cell surface. Immunization of a suitable host can be carried out in a number of ways. Nucleic acid sequences encoding a polypeptide of the invention or immunogenic fragments thereof, can be provided to the host in a delivery vehicle that is taken up by immune cells of the host. The cells will in turn express the receptor on the cell surface generating an immunogenic response in the host. Alternatively, nucleic acid sequences encoding the polypeptide, or immunogenic fragments thereof, can be expressed in cells in vitro, followed by isolation of the polypeptide and administration of the polypeptide to a suitable host in which antibodies are raised.

Alternatively, antibodies against the polypeptide may, if desired, be derived from an antibody phage display library. A bacteriophage is capable of infecting and reproducing within bacteria, which can be engineered, when combined with human antibody genes, to display human antibody proteins. Phage display is the process by which the phage is made to
'display' the human antibody proteins on its surface. Genes from the human antibody gene libraries are inserted into a population of phage. Each phage carries the genes for a different antibody and thus displays a different antibody on its surface.

Antibodies made by any method known in the art can then be purified from the host. Antibody purification methods may include salt precipitation (for example, with ammonium sulfate), ion exchange chromatography (for example, on a cationic or anionic exchange column preferably run at neutral pH and eluted with step gradients of increasing ionic strength), gel filtration chromatography (including gel filtration HPLC), and chromatography on affinity resins such as protein A, protein G, hydroxyapatite, and anti-immunoglobulin.

Antibodies can be conveniently produced from hybridoma cells engineered to express the antibody. Methods of making hybridomas are well known in the art. The hybridoma cells can be cultured in a suitable medium, and spent medium can be used as an antibody source. Polynucleotides encoding the antibody of interest can in turn be obtained from the hybridoma that produces the antibody, and then the antibody may be produced synthetically or recombinantly from these DNA sequences. For the production of large amounts of antibody, it is generally more convenient to obtain an ascites fluid. The method of raising ascites generally comprises injecting hybridoma cells into an immunologically naive histocompatible or immunotolerant mammal, especially a mouse. The mammal may be primed for ascites production by prior administration of a suitable composition (e.g., Pristane).

By "antibody mimetic" or "antibody mimic" is meant a molecule which specifically binds an antigen, but is not structurally related to antibodies. Typically, antibody mimetics specifically binding to a target are produced by screening libraries of mutagenized molecular scaffolds. Examples of molecular scaffolds include, without limitation, a fibronectin III (FN3) domain. The molecular scaffold is typically a smaller molecule than an antibody (e.g., about 50-200 residues). Examples of antibody mimetics include, without limitation, affibodies, affilins, affitins, anticalins, avimers, DARPins, Kunitz domain derived peptides, knottins and monobodies. In particular embodiments, an antibody mimic of the invention is a monobody specifically binding to the PIF pocket of Aurora A kinase.

As used herein, "affinity" or "binding affinity" refers to the strength of binding of an agent to another agent (in particular, binding of a polypeptide to another polypeptide). An exemplary quantitative measure of affinity is the dissociation constant, $K_d$. The $K_d$ is a measure relating concentrations of unbound agents with concentrations of bound agents at
equilibrium. For example, in an exemplary binding reaction, an agent (A) binds to another agent (B) to form a complex (AB). The dissociation constant, \( K_d \), for the binding between A and B is \( K_d = [A][B] / [AB] \), where [A] is the concentration of unbound A at equilibrium, [B] is the concentration of unbound B at equilibrium, and [AB] is the concentration of A and B bound together (i.e., concentration of bound A or bound B) at equilibrium. A high affinity of A to B is reflected in low concentrations of unbound A and unbound B and high concentrations of A bound to B at equilibrium. Low concentrations of unbound A and unbound B and high concentrations of A bound to B at equilibrium yield a low \( K_d \) value. Thus, the \( K_d \) is inversely related to affinity; a lower value of \( K_d \) indicates a higher affinity.

By "agent" is meant any small molecule chemical compound, antibody, nucleic acid molecule, or polypeptide, or fragments thereof.

By "allosteric regulation," "allosteric control," or "allosteric modulation" of polypeptide activity is meant modulation of activity of the polypeptide via binding of an effector molecule to a site other than the polypeptide's active site. Binding of the effector molecule to this site (i.e., the "allosteric site") may induce conformational changes in the polypeptide that alters the active site, thereby altering the polypeptide's activity. The TPX2 polypeptide is an exemplary allosteric regulator of kinase activity of a polypeptide. TPX2 polypeptide binds to the PIF pocket of Aurora A kinase, an allosteric site on Aurora A kinase. TPX2 polypeptide does not bind to the Aurora A kinase ATP-binding site, the active site of Aurora A kinase. Binding of TPX2 polypeptide to the PIF pocket of Aurora A kinase activates kinase activity of Aurora A kinase. In some embodiments, a monobody of the invention is an allosteric regulator of kinase activity of Aurora A kinase. In particular embodiments, a monobody of the invention binds to the allosteric site (i.e., PIF pocket) of Aurora A kinase. In particular embodiments, binding of a monobody of the invention to the allosteric site inhibits or activates kinase activity of Aurora A kinase.

By "ameliorate" is meant decrease, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease. Diseases include cancers characterized by an increase in Aurora A kinase activity.

By "alteration" is meant a change (increase or decrease) in the expression levels or activity of a gene or polypeptide as detected by standard art known methods such as those described herein. As used herein, an alteration includes a 10% change in expression levels, preferably a 25% change, more preferably a 40% change, and most preferably a 50% or
greater change in expression levels. In one embodiment, a monobody of the invention alters Aurora A kinase activity by at least about 5%, 10%, 15%, 20%, 25% or more.

By "analog" is meant a molecule that is not identical, but has analogous functional or structural features. For example, a polypeptide analog retains the biological activity of a corresponding naturally-occurring polypeptide, while having certain biochemical modifications that enhance the analog's function relative to a naturally occurring polypeptide. Such biochemical modifications could increase the analog's protease resistance, membrane permeability, or half-life, without altering, for example, ligand binding. An analog may include an unnatural amino acid. By "Aurora A," "Aurora A kinase," or "Aurora A polypeptide" is meant a polypeptide or fragment thereof having at least about 85% or greater amino acid identity to the amino acid sequence provided at NCBI Accession No. NP_940839 and having serine/threonine kinase activity. An exemplary polypeptide sequence of Aurora A kinase is provided below (SEQ ID NO: 7):

```
1 mdrskenci gvpkatapvg gpkrvlvtqg fpqcqplpvn sggaqrvclp snnssqiplq
25 61 agkivshkpv vqnpqkqplq plntptpvsr plpsapnplp eeelaskqkn
121 eelkgrrqwa edeeggplp kghkmvlkl pkgkmqkml kvklslqql kqyvqkrlrr
181 evelgshrl phnlgrygfg hdtayyilyl eyapgltyyv elqgklsqfd qgtatyitl
241 241 analshcrk vrlvhrldlpe nllgsagel knadfpwvsh apssrtttlc gtyldyplpem
301 iegrmnedeik dlwsvigclv eyflvqpprfe lomnqytyr krqevefipd ftyvrgaclvi
361 srlikhhp bqmnrleuveh wpisnksnpn sncqknkes kqpg
```

By "Aurora A polynucleotide" is meant a polynucleotide encoding an Aurora A polypeptide. An exemplary Aurora A polynucleotide sequence is provided at NCBI Accession No. NM_198437. The sequence is provided below (SEQ ID NO: 8):

```
1 acaagcgcag ccctgctcag cccggccca tcggctttctt agtcagaggg ttaactctct
25 61 attttaaag aagacaccttg aatcctttac agtcggagtc cggctccctt cggctccctt
121 ggtcgcagcg atcctagaccc atcaacagagct cggatccagtc tcggctccctt
181 agctgattga tcgctcagctg cagctggatgc ggcagctgag
241 241 attacattga aatcctttag agtcggagtc cggctccctt cggctccctt
301 cattctctta cagccctctgc atcggctcggct cggctccctt cggctccctt
361 gaagagattc cagggccgctgc cagctggatgc ggcagctgag
```

48 481 aacgtgaaat caaagcaaggg gacagctgag ctggctccctt cggctccctt
541 541 tggctccctt cggctccctt cggctccctt cggctccctt cggctccctt
601 601 cagctggatgc ggcagctgag ctggctccctt cggctccctt cggctccctt
661 661 tggctccctt cggctccctt cggctccctt cggctccctt cggctccctt
721 721 gtgctccctt cggctccctt cggctccctt cggctccctt cggctccctt
781 781 cagctggatgc ggcagctgag ctggctccctt cggctccctt cggctccctt
841 841 cggctccctt cggctccctt cggctccctt cggctccctt cggctccctt
901 901 cggctccctt cggctccctt cggctccctt cggctccctt cggctccctt
961 961 cggctccctt cggctccctt cggctccctt cggctccctt cggctccctt
1021 1021 cggctccctt cggctccctt cggctccctt cggctccctt cggctccctt
1081 1081 cggctccctt cggctccctt cggctccctt cggctccctt cggctccctt
1141 1141 cggctccctt cggctccctt cggctccctt cggctccctt cggctccctt
1201 1201 cggctccctt cggctccctt cggctccctt cggctccctt cggctccctt
1261 1261 cggctccctt cggctccctt cggctccctt cggctccctt cggctccctt
1321 1321 cggctccctt cggctccctt cggctccctt cggctccctt cggctccctt
1381 1381 cggctccctt cggctccctt cggctccctt cggctccctt cggctccctt
```

9
In this disclosure, "comprises," "comprising," "containing" and "having" and the like can have the meaning ascribed to them in U.S. Patent law and can mean "includes," "including," and the like; "consisting essentially of" or "consists essentially" likewise has the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.

The terms “binding,” “bind,” “bound” refer to an interaction between two molecules. The interaction may include a covalent or non-covalent bond. The interaction may also be reversible or irreversible depending on the type of interaction, such as covalent bond formation.

“Detect” refers to identifying the presence, absence or amount of the analyte to be detected.

By "detectable label," "detectable moiety," or "detectable tag" is meant a composition that when linked to a molecule of interest renders the latter detectable, via spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, or haptens.

By “disease” is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ. Examples of diseases include cancers characterized by an increase in an Aurora kinase.

By "effective amount" is meant the amount of a required to ameliorate the symptoms of a disease relative to an untreated patient. The effective amount of active agent(s) used to practice the present invention for therapeutic treatment of a disease varies depending upon...
the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an "effective" amount.

By "epitope tag" is meant a peptide sequence having immunoreactivity. Exemplary epitope tags include, but are not limited to V5-tag, Myc-tag, and HA-tag.

The invention provides a number of targets that are useful for the development of highly specific drugs to treat or a disorder characterized by the methods delineated herein. In addition, the methods of the invention provide a facile means to identify therapies that are safe for use in subjects.

By "fragment" is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.

By "fusion protein" or "fusion polypeptide" is meant a polypeptide or fragment thereof that combines at least two amino acid sequences that are not naturally contiguous. In some embodiments, a fusion polypeptide comprises an amino acid sequence encoding a monobody of the invention fused to an amino acid sequence encoding a supercharged polypeptide (e.g., a supercharged green fluorescent protein (GFP)). In other embodiments, the fusion polypeptide comprises an amino acid sequence encoding a monobody of the invention fused to an amino acid sequence encoding an epitope tag or a detectable tag.

"Hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases. For example, adenine and thymine are complementary nucleobases that pair through the formation of hydrogen bonds.

The terms "isolated," "purified," or "biologically pure" refer to material that is free to varying degrees from components which normally accompany it as found in its native state. "Isolate" denotes a degree of separation from original source or surroundings. "Purify" denotes a degree of separation that is higher than isolation. A "purified" or "biologically pure" protein is sufficiently free of other materials such that any impurities do not materially affect the biological properties of the protein or cause other adverse consequences. That is, a nucleic acid or peptide of this invention is purified if it is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques,
or chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, for example, polyacrylamide gel electrophoresis or high performance liquid chromatography. The term "purified" can denote that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. For a protein that can be subjected to modifications, for example, phosphorylation or glycosylation, different modifications may give rise to different isolated proteins, which can be separately purified.

By "isolated polynucleotide" is meant a nucleic acid (e.g., a DNA) that is free of the genes which, in the naturally-occurring genome of the organism from which the nucleic acid molecule of the invention is derived, flank the gene. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or that exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. In addition, the term includes an RNA molecule that is transcribed from a DNA molecule, as well as a recombinant DNA that is part of a hybrid gene encoding additional polypeptide sequence. "Polynucleotide" and "nucleic acid molecule" are used interchangeably herein.

Unless otherwise specified, a “polynucleotide encoding an amino acid sequence,” a "polynucleotide encoding a polypeptide,” or a “nucleotide sequence encoding an amino acid sequence,” includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. The phrase nucleotide sequence that encodes a polypeptide or an RNA may also include introns to the extent that the nucleotide sequence encoding the polypeptide may in some version contain an intron(s).

By an "isolated polypeptide" is meant a polypeptide of the invention that has been separated from components that naturally accompany it. Typically, the polypeptide is isolated when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, a polypeptide of the invention. An isolated polypeptide of the invention may be obtained, for example, by extraction from a natural source, by expression of a recombinant nucleic acid encoding such a polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.
By “monobody” is meant an antibody mimetic comprising a fibronectin type III domain (FN3) as a molecular scaffold. Monobodies are produced from combinatorial libraries in which portions of the FN3 scaffold are diversified using highly tailored mixtures of amino acids by utilizing phage display and yeast surface display techniques. These techniques have successfully generated a large number of monobodies that have high affinity and high specificity to their respective targets. Monobodies and methods of generating monobodies are further described in, for example, PCT/US2007/078039, U.S. Patent No. 6,673,901, and PCT/US2011/046160, which are incorporated herein in its entirety.

By “monobody Mb2” is meant a monobody or fragment thereof that binds an allosteric site on Aurora A kinase, increases Aurora A kinase activity, and has at least about 85% amino acid sequence identity to the following amino acid sequence:

AuroraA_2 (Mb2) (SEQ ID NO: 1)
SVSSVPTK LEVVAATPT SLISMDAGH QYEPVYYRI TYGETGGSNP VQEFTVPGY
STATISGLKPV GYDYTITVYA SWVDSYSSP ISINYRT

By “monobody Mb44” is meant a monobody or fragment thereof that binds an allosteric site on Aurora A kinase, reduces Aurora A kinase, and that has at least about 85% amino acid sequence identity to the following amino acid sequence:

AuroraA_44 (Mb44) (SEQ ID NO: 2)
SVSSVPTK LEVVAATPT SLISMDAPAV TVDFYVITYG ETGGYSFYQ EEFEPGSKST
ATISGLKPGY DYITTVYADY GQFYSPISI NYRT

By “monobody Mb51” is meant a monobody or fragment thereof that binds an allosteric site on Aurora A kinase and has at least about 85% amino acid sequence identity to the following amino acid sequence:

AuroraA_51 (Mb51) (SEQ ID NO: 3)
SVSSVPTK LEVVAATPT SLISMDAPFM SYEPVVYYRI TYGETGGNSP VQEFTVPGY
STATISGLKP GVDYTITVYA DSSSYYSSP ISINYRT

By “monobody Mb54” is meant a monobody that binds an allosteric site on Aurora A kinase, increases Aurora A kinase activity, and has at least about 85% amino acid sequence identity to the following amino acid sequence:

AuroraA_54 (Mb54) (SEQ ID NO: 4)
SVSSVPTK LEVVAATPT SLISMDAQTY QMVYVSSYR ITYGETGNS PVQEFTVPGY
YSTATISGLKP GVDYTITVYA ECGYSSYSP ISINYRT

By “monobody Mb56” is meant a monobody that binds an allosteric site on Aurora A kinase, decreases Aurora A kinase activity, and has at least 85% amino acid sequence identity to the following amino acid sequence:

AuroraA_56 (Mb56) (SEQ ID NO: 5)
By "monobody Mb60" is meant a monobody that binds an allosteric site on Aurora A kinase, decreases Aurora A kinase activity, and has at least 85% amino acid sequence identity to the following amino acid sequence:

AuroraA_60 (Mb60) (SEQ ID NO: 6)
SVSSVPTK LEVVAATFTS LLISWDAMSD WYYWVDYYRI TYGETGGSNP VQEFPTVFGSY
STATISGLKP GVIDYTITVYA SDDVWGDSYP ISINRT

By "marker" is meant any protein or polynucleotide having an alteration in expression level or activity that is associated with a disease or disorder.

By "mutation" is meant a change in a polypeptide or polynucleotide sequence relative to a wild-type reference sequence. Exemplary mutations include point mutations, missense mutations, amino acid substitutions, and frameshift mutations.

As used herein, "obtaining" as in "obtaining an agent" includes synthesizing, purchasing, or otherwise acquiring the agent.

By "phosphorylation rate" or "rate of phosphorylation" is meant the kinetic rate of a phosphorylation reaction catalyzed by a kinase. An exemplary measure of the rate is the value of a rate constant, $k$. The rate constant may be determined by plotting the concentrations of phosphorylated substrate against time, and fitting a curve or line to the concentration vs. time data. In some embodiments, the rate constant is determined by determining the slope of a line fit to concentrations of phosphorylated kemptide (substrate of Aurora A kinase) over time. The rate of phosphorylation may be dependent on assay conditions, such as temperature. Thus, an exemplary method of comparing effects of a modulator of Aurora A kinase (e.g., a monobody binding to an allosteric site of Aurora A) on Aurora A’s phosphorylation rate is to compare the rates of phosphorylation of Aurora A kinase contacted and not contacted with the modulator under identical or nearly identical assay conditions (e.g., same temperature).

By "reference" is meant a standard or control condition.

A "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset of or the entirety of a specified sequence; for example, a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence. For polypeptides, the length of the reference polypeptide sequence will generally be at least about 16 amino acids, preferably at least about 20 amino acids, more preferably at least about 25 amino acids, and even more preferably about 35 amino acids,
about 50 amino acids, or about 100 amino acids. For nucleic acids, the length of the reference nucleic acid sequence will generally be at least about 50 nucleotides, preferably at least about 60 nucleotides, more preferably at least about 75 nucleotides, and even more preferably about 100 nucleotides or about 300 nucleotides or any integer thereabout or therebetween.

Nucleic acid molecules useful in the methods of the invention include any nucleic acid molecule that encodes a polypeptide of the invention or a fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence, but will typically exhibit substantial identity. Polynucleotides having "substantial identity" to an endogenous sequence are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. Nucleic acid molecules useful in the methods of the invention include any nucleic acid molecule that encodes a polypeptide of the invention or a fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence, but will typically exhibit substantial identity.

Polynucleotides having "substantial identity" to an endogenous sequence are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. By "hybridize" is meant pair to form a double-stranded molecule between complementary polynucleotide sequences (e.g., a gene described herein), or portions thereof, under various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399; Kimmel, A. R. (1987) Methods Enzymol. 152:507).

For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and more preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and more preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment,
hybridization will occur at 37° C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 μg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42° C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 μg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

For most applications, washing steps that follow hybridization will also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include a temperature of at least about 25° C, more preferably of at least about 42° C, and even more preferably of at least about 68° C. In a preferred embodiment, wash steps will occur at 25° C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42° C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 68° C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al. (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001); Berger and Kimmel (Guide to Molecular Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.

By "specifically binds" is meant an agent (e.g., an antibody mimetic or monobody) that recognizes and binds a polypeptide (or fragment thereof) of the invention, but which does not substantially recognize and bind other molecules in a sample, for example, a biological sample, which naturally includes a polypeptide of the invention. An agent may also “specifically bind” to a particular site on a polypeptide, and not bind to other sites of the polypeptide. In some embodiments, an antibody mimetic or monobody specifically binds to an allosteric site (PIF pocket) of Aurora A kinase.

By "substantially identical" is meant a polypeptide or nucleic acid molecule exhibiting at least 50% identity to a reference amino acid sequence (for example, any one of
the amino acid sequences described herein) or nucleic acid sequence (for example, any one of
the nucleic acid sequences described herein). Preferably, such a sequence is at least 60%,
more preferably 80% or 85%, and more preferably 90%, 95% or even 99% identical at the
amino acid level or nucleic acid to the sequence used for comparison.

Sequence identity is typically measured using sequence analysis software (for
example, Sequence Analysis Software Package of the Genetics Computer Group, University
of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705,
BLAST, BESTFIT, GAP, or PILEUP/PRETTYBOX programs). Such software matches
identical or similar sequences by assigning degrees of homology to various substitutions,
deletions, and/or other modifications. Conservative substitutions typically include
substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine;
aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and
phenylalanine, tyrosine. In an exemplary approach to determining the degree of identity, a
BLAST program may be used, with a probability score between \( e^{-3} \) and \( e^{-100} \) indicating a
closely related sequence.

By "subject" is meant a mammal, including, but not limited to, a human or non-
human mammal, such as a bovine, equine, canine, ovine, or feline.

By “supercharged polypeptide” or “supercharged fragment” is meant a polypeptide or
fragment thereof, either engineered or naturally existing, with unusually high positive or net
negative net theoretical charge (typically > 1 net charge unit per kD of molecular weight). A
polypeptide may be engineered to be “supercharged” by substituting residues on the
polypeptide for residues having a charge. A polypeptide may also be “supercharged” by
fusion to a supercharged polypeptide. In some embodiments, a monobody of the invention is
supercharged by fusing the monobody to a supercharged green fluorescent protein (GFP).

Supercharged polypeptides having a negative net theoretical charge are
“supernegatively” charged; conversely, supercharged polypeptides having a positive net
theoretical charge are “superpositively” charged. Supercharged polypeptides typically
exhibit resistance to thermally or chemically induced aggregation. Supercharged
polypeptides may also be able to bind and penetrate cells (particularly, mammalian cells), and
can therefore deliver nucleic acid or protein cargoes into cells. In some embodiments, a
supercharged monobody of the invention (e.g., a monobody fused to a supercharged
polypeptide such as supercharged GFP) is delivered to a cell. In some other embodiments,
the supercharged monobody is delivered to a cell by cationic liposome mediated delivery.
Methods for engineering supercharged polypeptides for intracellular delivery of proteins into cells and for delivering supercharged polypeptides into a cell are described in, for example, Zuris et al. (2015), Nat. Biotechnol. 33, 73–80 and Liu et al. (2012), Methods Enzymol. 503: 293-319. By “TPX2 polypeptide” is meant a polypeptide or fragment thereof having at least about 85% or greater amino acid identity to the amino acid sequence provided at GenBank Accession Nos. EAW76422.1, EAW76421.1, and EAW76420.1 (various isoforms) and having TPX2 biological activity. Exemplary biological activities of TPX2 include, without limitation, binding to Aurora A kinase and mediating localization of Aurora A kinase to the spindles. The exemplary TPX2 polypeptide sequence at GenBank Accession No. EAW76422.1 is provided below (SEQ ID NO: 9):

```
1  mqvksysyys dapsdfinfs sldegdgtcng idswfeekan lenklglkng tggfgqgkt tp
 61  lrrkanqgai vtplpvpdnt yylkeakkenl vqgspinsnc ssleveaais rktqagqppr
121  srlsqxdkl egkekkhwhxm kaxkratpi ideilpskhm kvssnmkxx peeqshqgtda
181  eknnaspeka xkghtvpccpm pakgkflkst egeeleksmk mqqgevmmrk kneefkkklal
241  agiqgpqikks vsgvqtksvdf hfrtderikq hpknqgeyy hmpfvtexrh xsspavrtkg
301  ctivkpfnils gqkrgtfdet vstvplaqg vdfhkrtpn ryhllrkkkd ikktgcsvtvg
361  agvqwpdrhgs lgcqupglqks ssclsnplnl pskssvtkic rdqgpvtqgt hkraravteck
421  saelaeael egkgykkfka reldpircleg gplpgppppv xptepilgfd lelekeqgter
481  esikktedeh fethesrptic kiledvqevp ekkvlpitvps kpsfahkm lrmpktekedee
541  ederppikkaq pvpygyvpf kqplpaxite lpcrepsfrsd awqllqkekk xikelkgygepv
601  xfkalplpfh dtinipkxkv xnqvtlcqepfc letrdrgalx amqkNhleee lrrqggaeac
661  fkarptvncs qeppikrxxk xsxveglgsx lvqefqlat ekrakeqkel ekrmewegaq
721  qaqqleearl qeeeqkeel arlnrelvaq aniryxqggl eikssddqlt xpsvpxfstr
781  fhc
```

By "TPX2 polynucleotide" is meant a polynucleotide encoding a TPX2 polypeptide. An exemplary TPX2 polynucleotide sequence is provided at NCBI Accession No. NM_012112. The sequence is provided below (SEQ ID NO: 10):

```
1  agttgacctca cgccagggcc gggagaactaca cttccccagga acctccgggcc ccttggctcgg
30  cttctgtactt ccgcgtattgc ctcggtttctg acggtcaacttc gggagaactaca ccgccggtcc
61  attgttcctct ccgccggtcc ggtgctctgtg cagtgcatacg tccgaatggt gcctgctgctg
91  gccaagccgctg gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg
121  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
151  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
181  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
211  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
241  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
271  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
301  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
331  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
361  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
391  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
421  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
451  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
481  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
511  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
541  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
571  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
601  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
631  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
661  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
691  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
721  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
751  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
781  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
811  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
841  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
871  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
901  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
931  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
961  gggagaactaca cttcccggcc ccttgtaagc gcggggaggt gcctgctgctg gcctgctgctg
991  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
1021  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
1051  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
1081  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
1111  cgggctctgtg cttgctctgtg cgggctctgtg gcggggaggt gcctgctgctg gcctgctgctg
```

18
Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.

As used herein, the terms “treat,” “treating,” “treatment,” and the like refer to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.
Unless specifically stated or obvious from context, as used herein, the term "or" is understood to be inclusive. Unless specifically stated or obvious from context, as used herein, the terms "a", "an", and "the" are understood to be singular or plural.

Unless specifically stated or obvious from context, as used herein, the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.

The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1C are sets of exemplary plots depicting the monobody selection strategy used to generate monobodies in a study described herein. FIG. 1A is a set of plots showing enrichment of pools of monobodies that bind more strongly to Aurora A than Aurora A-TPX2 chimera. Dark grey dots represent 50 nM Aurora A. Light grey dots represent 50 nM AuroraA-TPX2. FIG. 1B is a set of plots showing further refinement of selection by using Y199H and Y199K Aurora A hotspot mutants in negative selection rounds of current monobody pools. FIG. 1C is a set of plots showing binding of isolated monobody clones to Aurora A wild type, Y199H mutant Aurora A, or Y199K mutant Aurora A in a yeast display format. The dissociation constant (K_d) shown in each plot is the K_d for binding to wild type Aurora A.

FIGS. 2A-2F are plots showing that monobodies in the study described herein (Mb2, Mb44, Mb51, Mb56, Mb54, and Mb60) bind to Aurora A kinase with nanomolar (nM) to low micromolar (μM) affinity. The plots show results of isothermal titration calorimetry experiments to measure the thermodynamics of the binding of monobodies Mb2 (FIG. 2A), Mb44 (FIG. 2B), Mb51 (FIG. 2C), Mb54 (FIG. 2D), Mb56 (FIG. 2E) and Mb60 (FIG. 2F) to dephosphorylated Aurora A (“deP AurA”). The dissociation constant (K_d), heat of enthalpy
(ΔH), and heat of entropy (ΔS) of each of the binding reactions are indicated in the respective figures.

FIG. 3 is a set of plots showing that monobodies in the study described herein (Mb2, Mb44, Mb51, Mb56, Mb54, and Mb60) can activate or inhibit Aurora A kinase activity. The top plot shows measurements of phosphorylation of kemptide (a peptide substrate for Aurora A kinase) when incubated with Aurora A kinase and TPX2, Mb2, Mb44, Mb51, Mb56, Mb54, and Mb60. The bottom plot shows a portion of the top plot, with the vertical axis re-scaled. The measurements indicate that the monobodies Mb2, Mb44, Mb51, Mb56, Mb54, and Mb60 modulate Aurora A kinase activity by activating or inhibiting Aurora A kinase activity, with various degrees of activation or inhibition.

FIGS. 4A-4E are images depicting the structural mechanism of inhibition or activation of Aurora A kinase by monobodies in the study described herein. FIG. 4A shows the inhibitory WY-motif of the monobody Mb60 (inhibitor of Aurora A kinase) “locks” an αC-helix of Aurora A in an inactive conformation (FIG. 4A). FIG. 4B is a magnified view of the structures depicted in FIG. 4A, showing contact between Mb60 and Aurora A kinase. FIG. 4C shows that activating anchor points of the monobody Mb54 (activator of Aurora A kinase) push on the αC-helix and coordinate Aurora A’s activation loop to keep the kinase in an active conformation. FIG. 4D shows a magnified view of the anchor points of Mb54. FIG. 4E shows how monobodies Mb60 (inhibitor) and Mb54 (activator) shift equilibria between active and inactive Aurora A kinase.

FIG. 5 shows purification of monobody Mb60 fused to supercharged GFP by gradient elution chromatography.

FIGS. 6A-6C are plots showing characterization of binding to Aurora A kinase and effect on Aurora A kinase activity of monobody Mb60 and monobody Mb60 fused to supercharged GFP (sGFP-Mb60). FIG. 6A is a plot showing Aurora A kinase activity when Aurora A kinase is incubated with monobody Mb60 (“Mb60”), monobody Mb60 fused to supercharged GFP (“sGFP_Mb60”), and no monobody (“no Mb”). FIG. 6A shows that Mb60 and sGFP-Mb60 both inhibit Aurora A kinase activity, but Mb60 more strongly inhibits Aurora A kinase than sGFP-Mb60. FIG. 6B is a set of plots depicting measurement of the thermodynamics of binding of Mb60 fused to supercharged GFP to Aurora A kinase (FIG. 6B) and binding of Mb60 to Aurora A kinase (FIG. 6C) using isothermal titration calorimetry. The dissociation constant (Kₐ) of the binding reaction is indicated in the respective plots.
FIGS. 7A-7C are micrographs showing live cell images during optimization of delivery of monobody Mb60 fused to supercharged GFP (sGFP-Mb60) into cells using cationic liposomes. FIG. 7A depicts the optimization of delivery of sGFP-Mb60 ("sGFP_Mb60") to cells. To optimize delivery, various concentrations (1 nM, 25 nM, 50 nM, and 500 nM) of sGFP-Mb60 were incubated with various amounts of cationic liposomes (2 µl, 3 µl, and 4 µl), and delivery of sGFP-Mb60 was assayed by live cell imaging. Optimal delivery was achieved at a combination of 50 nM sGFP-Mb60 and 4 µl cationic liposomes (FIG. 7B). FIG. 7C shows monitored delivery of sGFP-Mb60 to cells, at various incubation time points (0 hr, 1 hr, 7 hr, and 24 hr).

FIGS. 8A-8H are a series of micrographs showing intracellular locations of Aurora A kinase and monobody Mb60 fused to supercharged GFP (sGFP-Mb60) during various stages of the cell cycle. FIG. 8A shows high magnification views of DNA, Aurora A kinase ("AurA"), and sGFP-Mb60 ("sGFP Mb60") during interphase, prophase, prometaphase, and metaphase. The micrographs at the top of FIG. 8A show visualization of Aurora A kinase in a cell during prophase (left) and metaphase (right) in a study described in Bischhoff et al. (1998) EMBO J., 17(11):3052-65. FIG. 8A shows co-localization of sGFP-Mb60 with Aurora A kinase during prophase, prometaphase, and metaphase. FIG. 8B is a set of micrographs depicting high magnification views of subsets of micrographs in FIG. 8A. The micrographs show DNA, Aurora A kinase ("AurA"), and sGFP-Mb60 in a cell during interphase (left column), prophase (middle column), and metaphase (right column). FIGS. 8C-8E are sets of micrographs further showing co-localization of sGFP-Mb60 with Aurora A kinase during metaphase. In each of FIGS. 8C-8E, the set of micrographs on the left show high magnification views of DNA, Aurora A kinase ("AurA"), and sGFP-Mb60 in a cell. The micrograph on the right of each of FIGS. 8C-8E is a low magnification view of the micrographs in the left, showing DNA (FIG. 8C), Aurora A kinase (FIG. 8D), and sGFP-Mb60 (FIG. 8E). FIG. 8F is a set of micrographs showing a low magnification view of micrographs in FIG. 8A showing DNA, Aurora A kinase, and sGFP-Mb60 in a cell in prometaphase. FIG. 8G is a set of micrographs showing a low magnification view of micrographs in FIG. 8A showing DNA, Aurora A kinase, and sGFP-Mb60 in a cell in interphase.

FIG. 9 is a set of micrographs showing DNA, Aurora A kinase, and TPX2 in a cell in prometaphase.
FIG. 10 is an image showing a setup of an experiment measuring cell death. FIG. 10 shows a 12-well plate containing samples of human embryonic kidney (HEK) cells with sGFP-Mb60 delivered via liposomes and appropriate control cells. Cell death in cell samples treated with sGFP-Mb60 (inhibitor of Aurora A kinase activity) was observed.

5   DETAILED DESCRIPTION OF THE INVENTION

The invention features compositions and methods that are useful for modulating kinase activity in a cell. The invention is based, at least in part, on the discovery that monobodies generated to specifically bind to a PIF pocket in Aurora A kinase differentially modulated Aurora A’s kinase activity. The monobodies were found to activate or inhibit kinase activity of Aurora A, with varying strengths of activation or inhibition. Treatment of cells with monobodies inhibiting Aurora A activity was found to disrupt TPX2 binding to Aurora A, disrupt Aurora A localization to the spindles, and trigger cell death.

15 Antibody mimetics targeting an allosteric site (PIF pocket) of Aurora A kinase

Aurora A is an oncoprotein that is overexpressed in a multitude of cancers. Aurora A kinase is implicated in the regulation of mitotic entry and progression, spindle assembly, and spindle stability. Deregulation of Aurora A’s kinase activity can result in defects in spindle assembly, chromosome alignment, and cytokinesis. Without intending to be bound by theory, overexpression of Aurora A kinase is believed to contribute to tumor formation, growth, and proliferation.

Thus, ways to inhibit Aurora A via small molecules have been actively pursued by researchers in both academia and industry. In particular, efforts to develop small molecule inhibitors of Aurora A’s kinase activity have focused primarily on targeting Aurora A’s ATP-binding site. However, these efforts generally have not focused on targeting the PIF pocket of Aurora A, an allosteric site on Aurora A. The allosteric site of Aurora A is bound by TPX2. In order to localize to the spindle microtubules and allow for proper progression of mitosis, Aurora A must bind to TPX2, and must be allosterically activated by TPX2. Binding of TPX2 to the PIF pocket of Aurora A allosterically activates Aurora A. Inhibitors of kinase activity of Aurora A that bind to the PIF pocket in Aurora A are not previously known.

Targeting the allosteric site (i.e., PIF pocket) of Aurora A kinase offers a more attractive strategy for inhibiting Aurora A’s kinase activity. Unlike the ATP-binding pocket (the major target to date for kinase inhibitors as cancer drugs), which is highly conserved
across kinases, the allosteric PIF pocket of human protein kinases is variable among different kinases, thereby offering the potential of developing much more specific kinase inhibitors. Using a highly specific kinase inhibitor is less likely to result in side effects.

Accordingly, the present invention features antibody mimetics, such as monobodies, that specifically bind to an allosteric site of Aurora A kinase. Monobodies are not routinely explored in the kinase field. Not many monobodies are known to bind kinases, although few examples are known (e.g., monobodies that bind to Abl).

In some embodiments, the antibody mimetic or monobody specifically binds to the PIF pocket of Aurora A kinase. In some other embodiments, binding of the antibody mimetic or monobody disrupts binding of TPX2 to Aurora A kinase. The PIF pocket is a highly malleable interface that is ideal for drug discovery. Because the interaction surface between Aurora A and TPX2 is extensive and lacks the classic, small, confined, binding pocket that is preferred when designing small molecule inhibitors, an antibody mimic or monobody could mimic best the TPX2 interaction and thus displace this protein.

Further, due to phage display selection, antibody mimetics or monobodies having high selectivity and high affinity to the activation pocket (PIF pocket) of Aurora A could be generated. Also, using a small protein (such as a monobody) with high specificity for Aurora A instead of a small molecule compound (which tend to have low specificity) to inhibit Aurora A’s kinase activity poses a lower risk of side effects.

Antibody mimetics or monobodies of the invention are highly specific to Aurora A kinase and have high affinity to Aurora A kinase. In some embodiments, antibody mimetics or monobodies of the invention bind Aurora A with affinities of at least about 1 nM, least about 5 nM, at least about 10 nM, least about 50 nM, least about 100 nM, least about 500 nM, least about 1 µM, at least about 5 µM, or at least about 10 µM.

Antibody mimetics or monobodies of the invention are also capable of differentially modulating the kinase activity of Aurora A kinase. In some embodiments, binding of the antibody mimic or monobody to the allosteric site alters an activity of Aurora A kinase. In some embodiments, the antibody mimic or monobody modulates Aurora A’s activity such that the rate of phosphorylation of a substrate by Aurora A kinase is increased by at least about 1.1-fold, at least about 1.2-fold, at least about 1.3-fold, at least about 1.4-fold, at least about 1.5-fold, at least about 1.6-fold, at least about 1.7-fold, at least about 1.8-fold, at least about 1.9-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about
9 fold, at least about 10 fold, at least about 15 fold, and at least about 20 fold relative to a reference rate. In some other embodiments, the antibody mimetic or monobody modulates Aurora A’s activity such that the rate of phosphorylation of a substrate by Aurora A kinase is decreased by at least about 1.1 fold, at least about 1.2 fold, at least about 1.3 fold, at least about 1.4 fold, at least about 1.5 fold, at least about 1.6 fold, at least about 1.7 fold, at least about 1.8 fold, at least about 1.9 fold, at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 6 fold, at least about 7 fold, at least about 8 fold, at least about 9 fold, or at least about 10 fold relative to a reference rate. The reference rate may be, for example, the rate of phosphorylation of unbound Aurora A kinase (e.g. Aurora A kinase that is not contacted with any agent, such as TPX2) measured under substantially identical conditions (e.g., same temperature).

In particular embodiments, the antibody mimetic or monobody binds to the PIF pocket of Aurora A and inhibits or decreases Aurora A’s kinase activity. In some embodiments, when an inhibitory antibody mimetic or monobody is added to an Aurora A-catalyzed reaction, the rate of Aurora A’s phosphorylation of a substrate is decreased by at least about 1.1 fold, at least about 1.2 fold, at least about 1.3 fold, at least about 1.4 fold, at least about 1.5 fold, at least about 1.6 fold, at least about 1.7 fold, at least about 1.8 fold, at least about 1.9 fold, at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 6 fold, at least about 7 fold, at least about 8 fold, at least about 9 fold, or at least about 10 fold. In other embodiments, the antibody or monobody binds to the PIF pocket of Aurora A and activates Aurora A’s kinase activity. In particular embodiments, when an activating antibody mimetic or monobody is added to an Aurora A-catalyzed reaction, the rate of Aurora A’s phosphorylation of a substrate is increased by at least about 1.1 fold, at least about 1.2 fold, at least about 1.3 fold, at least about 1.4 fold, at least about 1.5 fold, at least about 1.6 fold, at least about 1.7 fold, at least about 1.8 fold, at least about 1.9 fold, at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 6 fold, at least about 7 fold, at least about 8 fold, at least about 9 fold, at least about 10 fold, at least about 15 fold, and at least about 20 fold.

Antibody mimetics or monobodies of the invention were generated using a novel screening assay. The screening assay comprised (a) contacting a candidate antibody mimetic with an Aurora A kinase having an unbound allosteric site, (b) contacting the candidate antibody mimetic with an Aurora A kinase having a bound allosteric site or an Aurora A kinase mutant that has a mutation within an allosteric site, and (c) measuring
binding of the candidate antibody mimetic with Aurora A kinase in step (a) and in step (b). A candidate antibody mimetic having an increased binding to Aurora A kinase in step (a) relative to step (b) was then identified as a potential antibody mimetic that specifically bound to an allosteric site (PIF pocket) of Aurora A kinase.

The screening assay for generating antibody mimetics or monobodies of the invention overcomes problems associated with generation of monobodies binding to other sites of Aurora A (e.g., Aurora A’s ATP binding site). As described elsewhere herein, antibody mimetics or monobodies specifically binding a target are typically generated by sorting libraries of antibody mimetics for those that bind the desired target (e.g., Aurora A). However, merely selecting antibody mimetics or monobodies for those binding to Aurora A generates monobodies that potentially bind to any site on Aurora A, rather than monobodies that bind specifically to the allosteric site (PIF pocket) of Aurora A. Thus, to select only those antibody mimetics or monobodies that specifically bound the allosteric site (PIF pocket) of Aurora A, in addition to performing a first round of selection for antibody mimetics or monobodies binding to Aurora A, a second round of selection for antibody mimetics or monobodies that did not bind to an Aurora A-TPX2 chimeric construct (i.e., Aurora A kinase having a bound PIF pocket or allosteric site) or an Aurora A kinase mutant that has a mutation within an allosteric site was performed. The second round of negative selection for monobodies using the mutant Aurora A ensured that monobodies binding to other portions of Aurora A (e.g., ATP-binding site) were eliminated from the screen, thus enriching the pool of monobodies with only those binding to the allosteric site (PIF pocket) of Aurora A kinase.

The structure of the antibody mimetics or monobodies of the present invention are advantageous for multiple applications because they (1) lack disulfide bonds, rendering them resistant against reducing agents; (2) are very stable even at high temperature; and (3) can be produced in a bacterial expression system with yields of up to 50-100 mg per liter of culture. Moreover, because they are derived from the endogenous human protein fibronectin, which is non-immunogenic, it is believed that the antibody mimetics or monobodies will not elicit an immune response. As a small, single-chain molecule, DNA encoding the antibody mimetics or monobodies can be incorporated into gene delivery vectors (e.g. viral vectors, liposomes) for cell or tissue-specific gene expression. As a result of these properties, the antibody mimetics or monobodies of the present invention can be used to treat or prevent a number of cancers or Aurora A-associated diseases or disorders.
as well as for diagnostic imaging of Aurora A-expressing tissues (e.g., tumors or cancers overexpressing Aurora A). Accordingly, the invention provides methods of producing recombinant polypeptides comprising antibody mimetics or monobodies specifically binding to Aurora A’s PIF pocket and methods of using these polypeptides to treat a cancer or an Aurora A-associated disease.

Recombinant Polypeptide Expression

The invention provides recombinant antibody mimetics (in particular, monobodies) and fusion polypeptides comprising the antibody mimetics, which are useful for treating a cancer or inhibiting growth and/or proliferation of a cancer in a subject. When delivered to a cell (particularly a cancer cell), the polypeptides of the invention modulate or inhibit Aurora A’s kinase activity in a cell, disrupt TPX2 binding to Aurora A kinase, and/or disrupt Aurora A’s localization to the spindles. Inhibition of Aurora A’s kinase activity and/or disruption of any of Aurora A’s other activities (e.g., binding with TPX2 or localization to the spindles) causes cell death.

Recombinant polypeptides of the invention are produced using virtually any method known to the skilled artisan. Typically, recombinant polypeptides are produced by transformation of a suitable host cell with all or part of a polypeptide-encoding nucleic acid molecule or fragment thereof in a suitable expression vehicle. Accordingly, the invention provides methods of producing a polypeptide of the invention, the method comprising (a) heterologously expressing an expression vector comprising a polynucleotide encoding the polypeptide in a host cell; and (b) isolating the polypeptide from the host cell.

Those skilled in the field of molecular biology will understand that any of a wide variety of expression systems may be used to provide the recombinant protein. The precise host cell used is not critical to the invention. A polypeptide of the invention may be produced in a prokaryotic host (e.g., *E. coli*) or in a eukaryotic host (e.g., *Saccharomyces cerevisiae*, insect cells, e.g., Si21 cells, or mammalian cells, e.g., NIH 3T3, HeLa, COS cells). Such cells are available from a wide range of sources (e.g., the American Type Culture Collection, Rockland, Md.; also, see, e.g., Ausubel et al., Current Protocol in Molecular Biology, New York: John Wiley and Sons, 1997). The method of transformation or transfection and the choice of expression vehicle will depend on the host system selected. Transformation and transfection methods are described, e.g., in Ausubel et al. (supra); expression vehicles may be

A variety of expression systems exist for the production of the polypeptides of the invention. Expression vectors useful for producing such polypeptides include, without limitation, chromosomal, episomal, and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof.

In some embodiments, the polypeptides of the invention are produced in a bacterial expression system with yields of up to 50-100 mg per liter of culture. One particular bacterial expression system for polypeptide production is the E. coli pET expression system (e.g., pET-28) (Novagen, Inc., Madison, Wis). According to this expression system, DNA encoding a polypeptide is inserted into a pET vector in an orientation designed to allow expression. Since the gene encoding such a polypeptide is under the control of the T7 regulatory signals, expression of the polypeptide is achieved by inducing the expression of T7 RNA polymerase in the host cell. This is typically achieved using host strains that express T7 RNA polymerase in response to IPTG induction. Once produced, recombinant polypeptide is then isolated according to standard methods known in the art, for example, those described herein.

Another bacterial expression system for polypeptide production is the pGEX expression system (Pharmacia). This system employs a GST gene fusion system that is designed for high-level expression of genes or gene fragments as fusion proteins with rapid purification and recovery of functional gene products. The protein of interest is fused to the carboxyl terminus of the glutathione S-transferase protein from Schistosoma japonicum and is readily purified from bacterial lysates by affinity chromatography using Glutathione Sepharose 4B. Fusion proteins can be recovered under mild conditions by elution with glutathione. Cleavage of the glutathione S-transferase domain from the fusion protein is facilitated by the presence of recognition sites for site-specific proteases upstream of this domain. For example, proteins expressed in pGEX-2T plasmids may be cleaved with thrombin; those expressed in pGEX-3X may be cleaved with factor Xa.

Alternatively, recombinant polypeptides of the invention are expressed in Pichia pastoris, a methiotrophic yeast. Pichia is capable of metabolizing methanol as the sole
carbon source. The first step in the metabolism of methanol is the oxidation of methanol to formaldehyde by the enzyme, alcohol oxidase. Expression of this enzyme, which is coded for by the AOX1 gene is induced by methanol. The AOX1 promoter can be used for inducible polypeptide expression or the GAP promoter for constitutive expression of a gene of interest.

Once the recombinant polypeptide of the invention is expressed, it is isolated, for example, using affinity chromatography. In one example, an antibody (e.g., produced as described herein) raised against a polypeptide of the invention may be attached to a column and used to isolate the recombinant polypeptide. In some embodiments, to facilitate purification of the recombinant polypeptide, the polypeptide comprises an epitope tag fused to antibody mimetic or monobody. The polypeptide is then isolated using an antibody against the epitope tag. Lysis and fractionation of polypeptide-harboring cells prior to affinity chromatography may be performed by standard methods (see, e.g., Ausubel et al., supra). Alternatively, the polypeptide is isolated using a sequence tag, such as a hexahistidine tag, that binds to nickel column. Once isolated, the recombinant protein can, if desired, be further purified, e.g., by high performance liquid chromatography (see, e.g., Fisher, Laboratory Techniques In Biochemistry and Molecular Biology, eds., Work and Burdon, Elsevier, 1980). Polypeptides of the invention, particularly short peptide fragments, can also be produced by chemical synthesis (e.g., by the methods described in Solid Phase Peptide Synthesis, 2nd ed., 1984 The Pierce Chemical Co., Rockford, Ill.). These general techniques of polypeptide expression and purification can also be used to produce and isolate useful peptide fragments or analogs (described herein).

In addition, or in the alternative, the polypeptides or fusion polypeptides of the invention may be produced using chemical methods to synthesize the desired amino acid sequence, in whole or in part. For example, polypeptides can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., Creighton (1983) Proteins: Structures And Molecular Principles, WH Freeman and Co, New York N.Y.). The composition of the synthetic polypeptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure).

Additionally, the amino acid sequence of a fusion polypeptide of the invention, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with a sequence from other subunits, or any part thereof, to produce a variant polypeptide.
Assays for Activity of Fusion Polypeptide

Any of the kinase activity and/or kinetics or binding assays known in the art or described herein may be used to measure the binding or effect on Aurora A kinase of the fusion polypeptides of the invention. For example, the inhibitory or activating effect of a fusion polypeptide comprising a monobody of the invention fused to a supercharged polypeptide (e.g., a supercharged GFP) may be measured by contacting the fusion polypeptide with Aurora A kinase in the presence of a substrate of Aurora A kinase (e.g., ATP, kemptide), and measuring a rate of phosphorylation of the substrate. The measured rate may be compared with a reference rate. The reference rate may be, for example, the rate of phosphorylation of the substrate by Aurora A kinase contacted with a monobody not fused to any other polypeptide. The reference rate may also be the rate of phosphorylation of the substrate by Aurora A kinase not contacted with any agent.

The rates are then compared to determine whether the fusion polypeptide comprising the monobody has similar activity to the monobody by itself (e.g., increases or decreases Aurora A’s kinase activity to the same degree, or to a lesser or greater degree). In some embodiments, the fusion polypeptide comprising a monobody fused to a supercharged polypeptide (e.g., a supercharged GFP) has activity that is identical or similar to the monobody not fused to another polypeptide. For example, a fusion polypeptide comprising a monobody fused to a supercharged polypeptide decreases or increases Aurora A’s kinase activity (e.g., rate of phosphorylation of a substrate) to a degree within about 5%, about 10%, or about 20% of the decrease or increase of Aurora A’s kinase activity by the monobody by itself. In some embodiments, the fusion polypeptide comprising an inhibitory monobody fused to a supercharged polypeptide inhibits Aurora A’s kinase activity to a lesser degree than inhibition of Aurora A kinase activity by the monobody by itself (i.e., not fused to another polypeptide).

Binding affinity of a fusion polypeptide to Aurora A kinase may also be measured according to methods known in the art or described herein. The affinity of binding of the fusion polypeptide comprising a monobody to Aurora A kinase may be compared to a reference affinity (e.g., the affinity of binding of the monobody by itself (not fused to another polypeptide) to Aurora A kinase). In some embodiments, the affinity of binding of the fusion polypeptide comprising a monobody fused to a supercharged polypeptide is within about 5%, about 10% or about 20% of the affinity of binding of the monobody by itself (i.e., not fused to another polypeptide) to Aurora A kinase.
Methods of Treatment

The present invention provides methods using polypeptides comprising antibody mimetics, monobodies, or fragments thereof, for treatment of cancer. As described herein, Aurora A kinase is overexpressed in many cancer types and is believed to contribute to cancer formation and growth. Antibody mimetics or monobodies of the invention are able to (1) inhibit activity of Aurora A and (2) disrupt Aurora A localization to the spindles. As described herein, inhibition of Aurora A’s kinase activity and disruption of localization of Aurora A to the spindles in a cell (in particular, a cancer cell) triggers cell death.

Thus, the present invention provides methods of inhibiting proliferation and/or reducing survival of a cancer cell and methods of treating a cancer or symptoms thereof, which comprise administering a therapeutically effective amount of a pharmaceutical composition comprising an antibody mimic, monobody, or fragment thereof (or a polynucleotide encoding the antibody mimic, monobody, or fragment thereof), herein to a subject (e.g., a mammal such as a human). One embodiment is a method of treating a subject suffering from or susceptible to a cancer or disorder or symptom thereof, particularly a cancer associated with overexpressed Aurora A kinase or deregulated Aurora A kinase activity. The method includes the step of administering to the mammal a therapeutic amount of the antibody mimic, monobody, or polynucleotide herein sufficient to treat the disease or disorder or symptom thereof, under conditions such that the disease or disorder is treated.

The methods herein include administering to the subject (including a subject identified as in need of such treatment) an effective amount of an antibody mimic, monobody, or polynucleotide described herein, or a composition described herein to produce such effect. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g., opinion) or objective (e.g., measurable by a test or diagnostic method).

As used herein, the terms “treat,” “treating,” “treatment,” and the like refer to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.

As used herein, the terms “prevent,” “preventing,” “prevention,” “prophylactic treatment” and the like refer to reducing the probability of developing a disorder or condition...
in a subject, who does not have, but is at risk of or susceptible to developing a disorder or condition.

The therapeutic methods of the invention (which include prophylactic treatment) in general comprise administration of a therapeutically effective amount of the agents herein, such as an antibody mimic, monobody, of fragment thereof (or a polynucleotide encoding the antibody mimic, monobody, of fragment thereof) herein to a subject (e.g., animal, human) in need thereof, including a mammal, particularly a human. Such treatment will be suitably administered to subjects, particularly humans, suffering from, having, susceptible to, or at risk for a disease, disorder, or symptom thereof. Determination of those subjects "at risk" can be made by any objective or subjective determination by a diagnostic test or opinion of a subject or health care provider (e.g., genetic test, enzyme or protein marker, activity or expression of Aurora A kinase, family history, and the like). The therapeutic agents herein may be also used in the treatment of any other disorders in which Aurora A kinase may be implicated.

In one embodiment, the invention provides a method of monitoring treatment progress. The method includes the step of determining a level of activity of a kinase (e.g., any target delineated herein modulated by an antibody mimic or monobody herein, such as Aurora A kinase) or diagnostic measurement (e.g., screen, assay) in a subject suffering from or susceptible to a disorder or symptoms thereof associated with Aurora A kinase, in which the subject has been administered a therapeutic amount of an antibody mimic, monobody, or polynucleotide herein sufficient to treat the disease or symptoms thereof. An activity of Aurora A may include, for example, Aurora A’s kinase activity, localization to the spindles, or functions during mitotic progress. The activity level of Aurora A determined in the method can be compared to known activity levels of Aurora A in either healthy normal controls or in other afflicted patients to establish the subject’s disease status. In preferred embodiments, a second activity level of Aurora A in the subject is determined at a time point later than the determination of the first level, and the two levels are compared to monitor the course of disease or the efficacy of the therapy. In certain preferred embodiments, a pre-treatment level of Aurora A activity in the subject is determined prior to beginning treatment according to this invention; this pre-treatment level of Aurora A activity can then be compared to the level of activity of Aurora A in the subject after the treatment commences, to determine the efficacy of the treatment.
Methods of Delivery

Antibody mimetics or monobodies of the invention, which are useful for specifically modulating or inhibiting Aurora A kinase in a cell, may be delivered to a cell (particularly a cancer cell) in any manner such that the antibody mimic or monobody is in functional form in the cell. The antibody mimic or monobody may be delivered to cells as polypeptides. Alternatively, a polynucleotide encoding an amino acid sequence of the antibody mimic or monobody may be delivered to cells for heterologous expression of the antibody mimic or monobody in the cells. Thus, the present invention features monobodies or polypeptides delivered to a cell by contacting the cell with a composition comprising the monobody or polypeptide or by heterologously expressing the monobody or polypeptide in the cell.

Intracellular Delivery of Polypeptides

Polypeptides of the invention, such as antibody mimetics or monobodies, may be delivered intracellularly to cells. The polypeptide must be delivered to the cells of a subject in a form in which they can be taken up so that therapeutically effective levels of the antibody mimic or monobody, or fragment thereof, is in functional form in the cells.

Methods of intracellular delivery of polypeptides are known to one of skill in the art. Exemplary methods of intracellular delivery of polypeptides include, without limitation, incorporation of the polypeptide into a liposome. Liposomes are phospholipid vesicles with sizes varying from 50 to 1000 nm, which can be loaded with polypeptides or other agents. Liposomal intracellular delivery of polypeptides into cells typically relies on endocytosis of the liposome-encapsulated polypeptide into the cell. Examples of suitable liposomes for intracellular delivery of polypeptides may be pH-sensitive liposomes. Such liposomes are made of pH-sensitive components; after being endocytosed in intact form, the liposome fuses with the endovacuolar membrane under lowered pH inside the endosome and destabilizes it, thereby releasing the contents (including the polypeptides encapsulated in the liposome) into the cytoplasm. The liposomes may also be further modified to enhance their stability or lifetime during circulation (e.g., by PEGylated liposomes). Liposomes may also be modified to specifically target antigens (e.g., “immunoliposomes” or liposomes embedded with antibodies an antigen). Antibody-bearing liposomes may have the advantages of targetability and facilitated uptake via receptor-mediated endocytosis.

Other methods of intracellular delivery of polypeptides include, without limitation, use of cell penetrating peptides (CPPs). A cell penetrating peptide or “CPP” is a protein or
peptide that can translocate through cellular membranes. A polypeptide for delivery into a
cell is fused with a CPP, thereby enabling or enhancing delivery of the polypeptide fusion
into the cell. Cell penetrating peptides include, for example, a trans-activating transcriptional
activator (TAT) from HIV-1, Antenapedia (Antp, a transcription factor in Drosophila), and
VP22 (a herpes virus protein).

Another exemplary method for intracellular delivery of polypeptides of the invention
is the use of supercharged proteins. Supercharged proteins or supercharged polypeptides are
a class of engineered or naturally existing polypeptides having an unusually high positive or
negative net theoretical charge. Membranes of cells are typically negatively charged.

Superpositively charged polypeptides are able to penetrate cells (particularly mammalian
cells), and associating cargo with superpositively charged polypeptides (e.g., polypeptides or
polynucleotides) can enable functional delivery of these macromolecules into cells, in vitro or
in vivo. Methods of generating supercharged polypeptides and using supercharged
polypeptides for intracellular polypeptide delivery are described in further detail in, for

The present invention features a monobody fused to a supercharged fragment
sufficient to mediate intracellular delivery of the polypeptide. Supercharged polypeptides (or
fusion polypeptides) may also be used in combination with charged liposomes to enable
efficient delivery of polypeptides in a cell. In some embodiments, the polypeptides (antibody
mimetics or monobodies) of the invention are delivered intracellularly by fusion of the
polypeptide with a supercharged polypeptide (e.g., supercharge green fluorescent protein
(GFP)). The supercharged polypeptide may be supernegatively charged. In some other
embodiments, the polypeptide fusions (e.g. antibody mimetic or monobody fused to a
supercharged polypeptide) are incorporated into a liposome. In particular embodiments, the
liposome is a cationic liposome. The cationic liposomes bearing supercharged antibody
mimetic or monody fusion are contacted with cells and efficiently delivered into the cells in
functional form.

Polynucleotide Therapy

Another therapeutic approach for treating a cancer or a disease associated with Aurora
A is polynucleotide therapy using a polynucleotide encoding an antibody mimetic or
monobody of the invention, or an antigen binding fragment thereof. Thus, provided herein
are isolated polynucleotides encoding an antibody mimetic or monobody of the invention, or an antigen binding fragment thereof. Expression of such polynucleotides or nucleic acid molecules in a cancer cell is expected to reduce survival of the cell and/or increase cell death. Such nucleic acid molecules can be delivered to cells of a subject having a cancer. The nucleic acid molecules must be delivered to the cells of a subject in a form in which they can be taken up so that therapeutically effective levels of the antibody mimetic or monobody, or fragment thereof, can be produced.

Transducing viral (e.g., retroviral, adenoviral, and adeno-associated viral) vectors can be used for somatic cell gene therapy, especially because of their high efficiency of infection and stable integration and expression (see, e.g., Cayouette et al., Human Gene Therapy 8:423-430, 1997; Kido et al., Current Eye Research 15:833-844, 1996; Bloomer et al., Journal of Virology 71:6641-6649, 1997; Naldini et al., Science 272:263-267, 1996; and Miyoshi et al., Proc. Natl. Acad. Sci. U.S.A. 94:10319, 1997). For example, a polynucleotide encoding an antibody mimetic or monobody, or a fragment thereof, can be cloned into a retroviral vector and expression can be driven from its endogenous promoter, from the retroviral long terminal repeat, or from a promoter specific for a target cell type of interest. Other viral vectors that can be used include, for example, a vaccinia virus, a bovine papilloma virus, or a herpes virus, such as Epstein-Barr Virus (also see, for example, the vectors of Miller, Human Gene Therapy 15:14, 1990; Friedman, Science 244:1275-1281, 1989; Eglitis et al., BioTechniques 6:608-614, 1988; Tolstoshev et al., Current Opinion in Biotechnology 1:55-61, 1990; Sharp, The Lancet 337:1277-1278, 1991; Cornetta et al., Nucleic Acid Research and Molecular Biology 36:311-322, 1987; Anderson, Science 226:401-409, 1984; Moen, Blood Cells 17:407-416, 1991; Miller et al., Biotechnology 7:980-990, 1989; Le Gal La Salle et al., Science 259:988-990, 1993; and Johnson, Chest 107:77S-83S, 1995).

Retroviral vectors are particularly well developed and have been used in clinical settings (Rosenberg et al., N. Engl. J. Med 323:370, 1990; Anderson et al., U.S. Pat. No. 5,399,346). In some embodiments, a viral vector is used to administer a polynucleotide encoding an antibody mimetic or monobody (or fragment thereof) systemically.

Non-viral approaches can also be employed for the introduction of therapeutic to a cell of a patient requiring inhibition of a cancer or induction of cell death in a cancer. For example, a nucleic acid molecule can be introduced into a cell by administering the nucleic acid in the presence of lipofection (Feigner et al., Proc. Natl. Acad. Sci. U.S.A. 84:7413, 1987; Ono et al., Neuroscience Letters 17:259, 1990; Brigham et al., Am. J. Med. Sci.
asialoorosomucoid-polylysine conjugation (Wu et al., Journal of Biological Chemistry
263:14621, 1988; Wu et al., Journal of Biological Chemistry 264:16985, 1989), or by micro-
injection under surgical conditions (Wolff et al., Science 247:1465, 1990). Preferably the
nucleic acids are administered in combination with a liposome and protamine.

Gene transfer can also be achieved using non-viral means involving transfection in
vitro. Such methods include the use of calcium phosphate, DEAE dextran, electroporation,
and protoplast fusion. Liposomes can also be potentially beneficial for delivery of DNA into
a cell. Transplantation of normal genes into the affected tissues of a patient can also be
accomplished by transferring a normal nucleic acid into a cultivatable cell type ex vivo (e.g.,
an autologous or heterologous primary cell or progeny thereof), after which the cell (or its
descendants) are injected into a targeted tissue.

cDNA expression for use in polynucleotide therapy methods can be directed from any
suitable promoter (e.g., the human cytomegalovirus (CMV), simian virus 40 (SV40), or
metallothionein promoters), and regulated by any appropriate mammalian regulatory element.
For example, if desired, enhancers known to preferentially direct gene expression in specific
cell types can be used to direct the expression of a nucleic acid. The enhancers used can
include, without limitation, those that are characterized as tissue- or cell-specific enhancers.
Alternatively, if a genomic clone is used as a therapeutic construct, regulation can be
mediated by the cognate regulatory sequences or, if desired, by regulatory sequences derived
from a heterologous source, including any of the promoters or regulatory elements described
above.

Pharmaceutical Compositions

The present invention features compositions useful for treating a cancer in a subject.
In some embodiments, the composition comprises an antibody mimetic, monobody, or
fragment thereof, that specifically binds to an allosteric site (PIF pocket) of Aurora A kinase.
In some other embodiments, the composition comprises a polynucleotide encoding an amino
acid sequence of the antibody mimetic, monobody, or fragment thereof. In particular
embodiments, the composition further comprises a liposome.

The administration of a composition comprising an antibody mimetic, monobody, or
polynucleotide herein for the treatment of a cancer may be by any suitable means that results
in a concentration of the therapeutic that, combined with other components, is effective in
ameliorating, reducing, or stabilizing a cancer in a subject. The composition may be
administered systemically, for example, formulated in a pharmaceutically-acceptable buffer
such as physiological saline. Preferable routes of administration include, for example,
subcutaneous, intravenous, interperitoneal, intramuscular, or intradermal injections that
provide continuous, sustained levels of the agent in the patient. The amount of the
therapeutic agent to be administered varies depending upon the manner of administration, the
age and body weight of the patient, and with the clinical symptoms of the cancer. Generally,
amounts will be in the range of those used for other agents used in the treatment of cancer or
other diseases associated with Aurora A kinase, although in certain instances lower amounts
will be needed because of the increased specificity of the agent. A composition is
administered at a dosage that inhibits Aurora A activity or that decreases cancer cell
proliferation as determined by a method known to one skilled in the art.

The antibody mimic, monobody, or polynucleotide may be contained in any
appropriate amount in any suitable carrier substance, and is generally present in an amount of
1-95% by weight of the total weight of the composition. The composition may be provided
in a dosage form that is suitable for parenteral (e.g., subcutaneously, intravenously,
intramuscularly, or intraperitoneally) administration route. The pharmaceutical compositions
may be formulated according to conventional pharmaceutical practice (see, e.g., Remington:
The Science and Practice of Pharmacy (20th ed.), ed. A. R. Gennaro, Lippincott Williams &
Wilkins, 2000 and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C.

Pharmaceutical compositions according to the invention may be formulated to release
the active agent substantially immediately upon administration or at any predetermined time
or time period after administration. The latter types of compositions are generally known as
controlled release formulations, which include (i) formulations that create a substantially
constant concentration of the drug within the body over an extended period of time; (ii)
formulations that after a predetermined lag time create a substantially constant concentration
of the drug within the body over an extended period of time; (iii) formulations that sustain
action during a predetermined time period by maintaining a relatively, constant, effective
level in the body with concomitant minimization of undesirable side effects associated with
fluctuations in the plasma level of the active substance (sawtooth kinetic pattern); (iv)
formulations that localize action by, e.g., spatial placement of a controlled release
composition adjacent to or in contact with a tumor; (v) formulations that allow for convenient
dosing, such that doses are administered, for example, once every one or two weeks; and (vi) formulations that target a cancer using carriers or chemical derivatives to deliver the therapeutic agent to a particular cell type (e.g., cancer cell). For some applications, controlled release formulations obviate the need for frequent dosing during the day to sustain the plasma level at a therapeutic level.

Any of a number of strategies can be pursued in order to obtain controlled release in which the rate of release outweighs the rate of metabolism of the agent in question. In one example, controlled release is obtained by appropriate selection of various formulation parameters and ingredients, including, e.g., various types of controlled release compositions and coatings. Thus, the therapeutic is formulated with appropriate excipients into a pharmaceutical composition that, upon administration, releases the therapeutic in a controlled manner. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, molecular complexes, nanoparticles, patches, and liposomes.

The pharmaceutical composition may be administered parenterally by injection, infusion or implantation (subcutaneous, intravenous, intramuscular, intraperitoneal, or the like) in dosage forms, formulations, or via suitable delivery devices or implants containing conventional, non-toxic pharmaceutically acceptable carriers and adjuvants. The formulation and preparation of such compositions are well known to those skilled in the art of pharmaceutical formulation. Formulations can be found in Remington: The Science and Practice of Pharmacy, supra.

Compositions for parenteral use may be provided in unit dosage forms (e.g., in single-dose ampoules), or in vials containing several doses and in which a suitable preservative may be added (see below). The composition may be in the form of a solution, a suspension, an emulsion, an infusion device, or a delivery device for implantation, or it may be presented as a dry powder to be reconstituted with water or another suitable vehicle before use. Apart from the active agent that reduces or ameliorates a cancer, the composition may include suitable parenterally acceptable carriers and/or excipients. The active therapeutic agent(s) (e.g., an antibody mimic, monobody, or polynucleotide described herein) may be incorporated into microspheres, microcapsules, nanoparticles, liposomes, or the like for controlled release. Furthermore, the composition may include suspending, solubilizing, stabilizing, pH-adjusting agents, tonicity adjusting agents, and/or dispersing, agents.
In some embodiments, the composition comprising the active therapeutic (i.e., a monobody, antibody mimic, or polynucleotide herein) is formulated for intravenous delivery. As indicated above, the pharmaceutical compositions according to the invention may be in the form suitable for sterile injection. To prepare such a composition, the suitable therapeutic(s) are dissolved or suspended in a parenterally acceptable liquid vehicle. Among acceptable vehicles and solvents that may be employed are water, water adjusted to a suitable pH by addition of an appropriate amount of hydrochloric acid, sodium hydroxide or a suitable buffer, 1,3-butanediol, Ringer's solution, and isotonic sodium chloride solution and dextrose solution. The aqueous formulation may also contain one or more preservatives (e.g., methyl, ethyl or n-propyl p-hydroxybenzoate). In cases where one of the agents is only sparingly or slightly soluble in water, a dissolution enhancing or solubilizing agent can be added, or the solvent may include 10-60% w/w of propylene glycol or the like.

**Combination therapies**

Optionally, an anti-cancer therapeutic of the invention (e.g., an antibody mimic, monobody, or polynucleotide described herein) may be administered in combination with any other standard anti-cancer therapy; such methods are known to the skilled artisan and described in Remington's Pharmaceutical Sciences by E. W. Martin.

**Screening Assays using Monobodies**

Antibody mimetics or monobodies of the present invention are useful tools for investigating kinase activation mechanisms (particularly, activation of Aurora A kinase) in *vitro* and *in vivo*. Accordingly, the invention provides a method of modulating activity of an Aurora A kinase, the method comprising contacting the Aurora A kinase with an antibody mimetic or monobody of the invention. In some embodiments, the antibody mimic or monobody contacts Aurora A kinase in *vitro*. In other embodiments, the antibody mimic or monobody contacts Aurora A kinase in a cell. It is expected that use of a monobody to disrupt an extensive protein-protein interaction area will be useful for advancing research and investigation of mechanisms of kinase (particularly, Aurora A kinase) regulation and activities in cancer. The dual effect of disruption of allosteric activation and localization, and the specific effect of the monobodies on Aurora A’s function in the spindles while keeping its function in the centrosome intact offers a unique intrinsic control of Aurora A’s activities that may be useful in certain experiments, particularly live-cell imaging experiments using the
monobodies. To facilitate detection of the antibody mimetics or monobodies of the invention (particularly in live-cell imaging experiments), fusion polypeptides comprising an antibody mimetic or monobody fused to a detectable tag are provided herein.

5 Kits

The invention provides kits for the treatment or prevention of cancer, particularly cancers associated with overexpression of Aurora A kinase. In one embodiment, the kit includes a therapeutic or prophylactic composition containing an effective amount of an antibody mimetic, monobody, or fragment thereof (or a polynucleotide encoding such) in unit dosage form. In some embodiments, the kit comprises a sterile container which contains a therapeutic or prophylactic composition; such containers can be boxes, ampoules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container forms known in the art. Such containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding medicaments.

If desired a composition comprising a therapeutic agent (e.g., antibody mimetic, monobody, or polynucleotide) of the invention is provided together with instructions for administering the agent to a subject having or at risk of developing cancer. The instructions will generally include information about the use of the composition for the treatment or prevention of cancer. In other embodiments, the instructions include at least one of the following: description of the therapeutic agent; dosage schedule and administration for treatment or prevention of ischemia or symptoms thereof; precautions; warnings; indications; counter-indications; overdosage information; adverse reactions; animal pharmacology; clinical studies; and/or references. The instructions may be printed directly on the container (when present), or as a label applied to the container, or as a separate sheet, pamphlet, card, or folder supplied in or with the container.

The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are well within the purview of the skilled artisan. Such techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook, 1989); “Oligonucleotide Synthesis” (Gait, 1984); “Animal Cell Culture” (Freshney, 1987); “Methods in Enzymology” “Handbook of Experimental Immunology” (Weir, 1996); “Gene Transfer Vectors for Mammalian Cells” (Miller and Calos, 1987); “Current Protocols in
Molecular Biology” (Ausubel, 1987); “PCR: The Polymerase Chain Reaction”, (Mullis, 1994); “Current Protocols in Immunology” (Coligan, 1991). These techniques are applicable to the production of the polynucleotides and polypeptides of the invention, and, as such, may be considered in making and practicing the invention. Particularly useful techniques for particular embodiments will be discussed in the sections that follow.

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the assay, screening, and therapeutic methods of the invention, and are not intended to limit the scope of what the inventors regard as their invention.

EXAMPLES

Example 1: Generation of monobodies specifically binding to the PIF pocket of Aurora A kinase

A high-throughput yeast-display library screening of more than a million monobody clones to identify activating and inhibitory monobodies towards Aurora A kinase was performed. Using phage display and Aurora A constructs, monobody libraries were screened for monobodies that bound tightly to the PIF pocket of human Aurora A kinase (FIGS. 1A-1B). The selection scheme relied on (1) a round of positive selection that selected for monobodies binding more strongly to Aurora A than Aurora A-TPX2 chimera (FIG. 1A) and (2) further refinement of selection by using Y199H and Y199K Aurora A hotspot mutants in negative selection rounds of current monobody pools (FIG. 1B). From the screen, a number of monobodies specifically binding to and having a high affinity for the PIF pocket of Aurora A were identified (FIG. 1C). These monobodies were selected for further biochemical characterization.

Example 2: Biochemical characterization of monobodies specifically binding to the PIF pocket of Aurora A kinase

Monobodies Mb2, Mb44, Mb51, Mb56, Mb54, and Mb60 were selected for further biochemical characterization of the Aurora A- monobody interaction. Specifically, the affinity to Aurora A kinase and the ability of these monobodies to activate or inhibit the kinase activity of Aurora A kinase were measured.

Isothermal titration calorimetry (ITC) experiments using the monobodies were performed to determine the thermodynamics of the Aurora A - monobody interaction.
Results showed that the monobodies bound to Aurora A kinase with affinities ranging in the nanomolar (nM) to low micromolar (μM) range (FIGS. 2A-2F). The monobodies bound to Aurora A with higher affinity than TPX2’s affinity to Aurora A (affinity of TPX2 for Aurora A was measured to be 5μM).

Next, a quantitative High Performance Liquid Chromatography (HPLC)-based assay was established and used to determine the kinetics of Aurora A activation by the monobodies. Assay results showed that the monobodies had a differential effect on the kinase activity of Aurora A (FIG. 3). As shown in FIG. 3, at least one monobody (Mb54) showed activation of kinase activity of Aurora A. Several showed strong inhibition of Aurora A’s kinase activity (e.g., Mb60).

**Example 3: High-resolution X-ray crystallography structures of Aurora A in the presence of activating and inhibitory monobodies bound to the PIF pocket and ATP-competitive drug bound to the ATP pocket**

High-resolution X-ray crystallography structures of Aurora A in the presence of an activating (Mb54) bound to the PIF pocket, an inhibitory monobody (Mb60) bound to the PIF pocket, and ATP-competitive drugs bound to the ATP-binding pocket were solved. The high-resolution x-ray structures of complexes with activating and inhibiting monobodies with Aurora A revealed the mechanism of activation and inhibition of the kinase activity of Aurora A.

FIGS. 4A-4E depict the mechanism of inhibition of Aurora A’s kinase activity by inhibitory monobody Mb60 and activation of Aurora A’s kinase activity by activating monobody Mb54. The inhibitory WY-motif on Mb60 “locks” the αC-helix of Aurora A in an inactive conformation (FIGS. 4A-4B). The activator Mb54 activates Aurora A kinase activity via anchor points that “push” on the αC-helix of Aurora A (FIG. 4C). The activating anchor points of Mb54 (FIG. 4D) push on the αC-helix and coordinate Aurora A’s activation loop to keep the kinase in an active conformation. The monobodies shift equilibria between active and inactive Aurora A kinase (FIG. 4E).

**Example 4: Intracellular delivery of inhibitory monobodies by cationic liposome mediated delivery of monobodies fused to supercharged green fluorescent protein (GFP)**
The Aurora A – monobody interaction was further characterized in mammalian cells. To perform this characterization, monobodies were fused to a supercharged green fluorescent protein (GFP) and the monobody-supercharged GFP fusion polypeptides were delivered to HEK293 and HeLa cells using cationic liposomes according to the method described in Zuris et al. Nat. Biotechnol. (2015) 3373–80. Monobody Mb60 was fused to supercharged GFP and purified (FIG. 5). Next, biochemical characterization of the Mb60-supercharged GFP fusion (“sGFP-Mb60”) was performed. FIGS. 6A-6C show the affinity and the effect on Aurora A’s kinase activity of sGFP-Mb60 compared to Mb60. As shown in FIG. 6A, sGFP-Mb60 inhibited kinase activity of Aurora A. Mb60 showed stronger inhibition of kinase activity than sGFP-Mb60. FIGS. 6B-6C show the thermodynamics of binding of sGFP-Mb60 and Mb60 to Aurora A kinase. As indicated by the dissociation constant values (K_d) in the plots in FIGS. 6B-6C, Mb60 bound to Aurora A kinase with about 1.0 μM affinity (FIG. 6C), whereas sGFP-Mb60 bound Aurora A kinase at a lower affinity of about 9.9 μM (FIG. 6B).

Efficiency of delivery of sGFP-Mb60 into mammalian cells (HEK and HeLa cells) was then optimized. To optimize delivery, various concentrations (1 nM, 25 nM, 50 nM, and 500 nM) of sGFP-Mb60 were incubated with various amounts of cationic liposomes (2 μl, 3 μl, and 4 μl), and delivery of sGFP-Mb60 into cells was assayed by live cell imaging (FIG. 7A). Optimal delivery was achieved at a combination of 50 nM sGFP_Mb60 and 4 μl cationic liposomes (FIG. 7B). FIG. 7C shows delivery of sGFP-Mb60 to cells monitored at various time points (0 hr, 1 hr, 7 hr, and 24 hr).

Example 5: Co-localization of inhibitory monobody with Aurora A kinase during various cell cycle stages and mediation of cell death

Activity of the monobody Mb60 fused to supercharged GFP (“sGFP-Mb60”) in vivo was assayed by fluorescence microscopy. Aurora A kinase is implicated in regulation of mitotic progression, particularly spindle assembly and maintenance of the mitotic spindle. During the transition to mitosis, Aurora A kinase is known to localize to the centrosomes and the spindle, with levels and activity of Aurora A kinase peaking during this point.

FIG. 8A shows expression and localization of sGFP-Mb60 and Aurora A kinase in vivo during various stages of the cell cycle (interphase, prophase, prometaphase, and metaphase). As shown in FIG. 8A, during prophase, prometaphase, and metaphase, expression of Aurora A kinase is elevated. FIG. 8A further shows that sGFP-Mb60 co-
localized with Aurora A kinase during prophase, prometaphase, and metaphase. FIGS. 8B-8H provide the same micrographs shown in FIG. 8A, at different levels of magnification. In FIG. 9, *in vivo* localization of Aurora A kinase and TPX2 in during prometaphase is shown.

Delivery of sGFP-Mb60 into cells was found to disrupt the TPX2 / Aurora A interaction in the cells. It was also observed that delivery of sGFP-Mb60 disrupted Aurora A’s function in the spindles, but kept its function in the centrosome intact. For example, in FIG. 8A, Aurora A was observed to localize to the centrosomes during at least prophase and prometaphase. It was also observed that the cells stayed in prometaphase, and never entered anaphase. Cell death was also observed (FIG. 10). Without being bound by theory, it is believed that the inhibitory monobody sGFP-Mb60 disrupted Aurora A’s regulation of spindle assembly and/or maintenance, thereby inhibiting mitotic progression in the cells and causing cell death.

**Other Embodiments**

From the foregoing description, it will be apparent that variations and modifications may be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.

The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.
What is claimed is:

1. A fusion polypeptide comprising a first polypeptide and a second polypeptide fused to the first polypeptide, wherein the first polypeptide is an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, and the second polypeptide comprises at least one of the following: (i) a fragment sufficient to mediate intracellular delivery of the antibody mimetic, (ii) an epitope tag, and (iii) a detectable moiety.

2. The fusion polypeptide of claim 1, wherein the antibody mimetic is a monobody.

3. The fusion polypeptide of any one of claims 1-2, wherein the antibody mimetic comprises any one of the following sequences:
   AuroraA_2 (Mb2) (SEQ ID NO: 1)
   SVSSVPTK LEVVAATPTS LLISWDAPGH QYEPVYYYRI TYGETGGNSP VQEFTVPGY YSTATISGLKP GVDYTITYVA WYVDGSYSSP ISINYRT
   AuroraA_44 (Mb44) (SEQ ID NO: 2)
   SVSSVPTK LEVVAATPTS LLISWDAPAV TVDFYVITYG ETGGYSYPWQ EFEVPGKST ATISGLKPGY DYTITYJADY GQVFYPISPI NYRT
   AuroraA_51 (Mb51) (SEQ ID NO: 3)
   SVSSVPTK LEVVAATPTS LLISWDAPKM SYFVYYYRI TYGETGGNSP VQEFTVPGY YSTATISGLKP GVDYTITYVA DMSIYSSYSP ISINYRT
   AuroraA_54 (Mb54) (SEQ ID NO: 4)
   SVSSVPTK LEVVAATPTS LLISWDAGTY QMQDYVSYYR ITYGETGGNS PVQEFTVPGY YSTATISGLKP GVDYTITYVY AEGYISSYSP ISINYRT
   AuroraA_56 (Mb56) (SEQ ID NO: 5)
   SVSSVPTK LEVVAATPTS LLISWDADSQ WYYVDYJYRI TYGETGGNSP VQEFTVPGSY STATISGLKP GVDYTITYVA SSDWGDYSP ISINYRT
   AuroraA_60 (Mb60) (SEQ ID NO: 6)
   SVSSVPTK LEVVAATPTS LLISWDAPAV TVHYVITYG ETGGNSPVQE PTVPGKSTA TISGLKPGVD YTTYVASYIDF WYGGYSPI ISNYRT
4. The fusion polypeptide of any one of claims 1-3, wherein the fusion polypeptide binds to the allosteric site with affinity of at least about 1 nM, at least about 10 nM, at least about 100 nM, or at least about 1 μM.

5. The fusion polypeptide of any one of claims 1-4, wherein the allosteric site is a PIF pocket.

6. The fusion polypeptide of any one of claims 1-5, wherein binding of the fusion polypeptide to the allosteric site alters an activity of Aurora A kinase.

7. The fusion polypeptide of claim 6, wherein the fusion polypeptide binding decreases kinase activity of Aurora A kinase.

8. The fusion polypeptide of claim 7, wherein the fusion polypeptide binding disrupts binding of TPX2 to Aurora A kinase.

9. The fusion polypeptide of any of claims 2-8, wherein the fragment is a supercharged polypeptide.

10. An isolated polynucleotide encoding a fusion polypeptide of any one of claims 1-9.

11. An expression vector comprising a polynucleotide encoding an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, and the second polypeptide comprises at least one of the following: (i) a fragment sufficient to mediate intracellular delivery of the antibody mimetic, (ii) an epitope tag, and (iii) a detectable moiety.

12. The expression vector of claim 11, wherein the polynucleotide is the polynucleotide of claim 10.

13. The expression vector of claim 11, wherein the polynucleotide encodes an amino acid sequence of at least one monobody selected from the group consisting of: Mb2, Mb44, Mb51, Mb56, Mb54, and Mb60.

15. The cell of claim 14, wherein the cell is a prokaryote or eukaryote.

16. A method of producing a fusion polypeptide comprising an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, the method comprising
   (a) heterologously expressing an expression vector encoding the fusion polypeptide of any one of claims 1-9 in a host cell;
   (b) isolating the fusion polypeptide from the host cell.

17. The method of claim 16, wherein the expression vector is the expression vector of any one of claims 12-14.

18. The method of claim 17, wherein the host cell is the cell of any one of claims 14-15.

19. A pharmaceutical composition comprising an effective amount of an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase.

20. A pharmaceutical composition comprising an effective amount of the fusion polypeptide of any one of claims 1-9 or the polynucleotide or expression vector of any one of claims 10-13.

21. The pharmaceutical composition of any one of claims 19-20, further comprising a liposome.

22. The pharmaceutical composition of any one of claims 19-21, further comprising a pharmaceutically acceptable excipient.

23. The pharmaceutical composition of any one of claims 19-22, wherein the composition is formulated for intravenous delivery.
24. A method of identifying an antibody mimic that specifically binds to an allosteric site of Aurora A kinase, the method comprising
   (a) contacting a candidate antibody mimic with an Aurora A kinase having an unbound allosteric site,
   (b) contacting the candidate antibody mimic with an Aurora A kinase having a bound allosteric site or an Aurora A kinase mutant that has a mutation within an allosteric site, and
   (c) measuring binding of the candidate antibody mimic with Aurora A kinase in step (a) and in step (b), wherein a candidate antibody mimic having an increased binding to Aurora A kinase in step (a) relative to step (b) is identified as an antibody mimic that specifically binds to an allosteric site of Aurora A kinase.

25. The method of claim 25, wherein the antibody mimic is a monobody.

26. The method of any one of claims 25-26, wherein the allosteric site is a PIF pocket.

27. The method of any one of claims 25-26, wherein the Aurora A kinase having a bound allosteric site is Aurora A kinase bound with TPX2.

28. A method of modulating activity of an Aurora A kinase, the method comprising contacting the Aurora A kinase with a polypeptide comprising an antibody mimic, or antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, thereby modulating the activity of the Aurora A kinase.

29. A method of inhibiting proliferation and/or reducing survival of a cell, the method comprising contacting an Aurora A kinase in the cell with a polypeptide comprising an antibody mimic, or antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, thereby inhibiting proliferation and/or reducing survival of the cell.

30. A method of treating a cancer in a subject, the method comprising administering to the subject an effective amount of a composition comprising a polypeptide comprising an
antibody mimetic, or antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, thereby treating the cancer in the subject.

31. The method of any one of claims 28-30, wherein the antibody mimetic is a monobody.

32. The method of any one of claims 28-31, wherein the polypeptide is the fusion polypeptide of any one of claims 1-9.

33. The method of any one of claims 28-32, wherein the polypeptide is produced according to the method of claim 16.

34. The method of any one of claims 28-33, wherein the polypeptide binds to the allosteric site with affinity of at least about 1 nM, at least about 10 nM, at least about 100 nM, or at least about 1 μM.

35. The method of claim 34, wherein the allosteric site is a PIF pocket.

36. The method of claim 35, wherein binding of the polypeptide to the allosteric site alters an activity of Aurora A kinase.

37. The method of claim 36, wherein the polypeptide binding decreases kinase activity of Aurora A kinase.

38. The method of claim 36, wherein the polypeptide binding disrupts binding of TPX2 to Aurora A kinase.

39. The method of any one of claims 28 or 31-38, wherein the polypeptide contacts Aurora A kinase in vitro or in a cell.

40. The method of any one of claims 29 or 31-39, wherein the polypeptide is delivered to the cell by contacting the cell with a composition comprising the polypeptide or by heterologously expressing the polypeptide in the cell.
41. The method of any one of claims 30-40, wherein the composition further comprises a liposome.

42. The method of any one of claims 29 or 31-41, wherein the cell is a cancer cell.

43. The method of claim 30, wherein the subject is human.
FIG. 1B
CONTINUED
SHOWN Kd IS FOR WILD TYPE

FIG. 1C
**FIG. 2A**

- **Graph:**
  - Title: deP AurA + Mb2
  - X-axis: time (s)
  - Y-axis: μs
  - Data points show a decline over time.

- **Equations:**
  - $K_d = 8.7 \pm 4.5 \text{ nM}$
  - $n = 1.02$
  - $dH = -67.4 \pm 0.6 \text{ kJ/mol}$
  - $dS = -71.6 \pm 0.6 \text{ J/mol*K}$

**FIG. 2B**

- **Graph:**
  - Title: deP AurA + Mb44
  - X-axis: time (s)
  - Y-axis: μs
  - Data points show a decline over time.

- **Equations:**
  - $K_d = 2.6 \pm 0.2 \text{ μM}$
  - $n = 1.06$
  - $dH = -67.2 \pm 3.7 \text{ kJ/mol}$
  - $dS = -84.9 \pm 5.4 \text{ J/mol*K}$
Fig. 2C: 
- Graph showing time (s) vs. μL/s for deP AurA + Mb51.
- Kd = 27.4 ± 9.2 nM
- ΔH = -38.1 ± 0.6 kJ/mol
- ΔS = -16.9 ± 0.3 J/mol*K

Fig. 2D: 
- Graph showing time (s) vs. μL/s for deP AurA + Mb54.
- Kd = 174.7 ± 21.6 μM
- ΔH = -101.3 ± 1.3 kJ/mol
- ΔS = -210.3 ± 2.6 J/mol*K
FIG. 2E

FIG. 2F
FIG. 3
Aurora A + Mb60 + AMPPCP (3.27Å)

FIG. 4A
Aurora A + Mb54 + AMPPCP (2.06 Å)

FIG. 4C
FIG. 4E

**INACTIVE**
Aurora A + inhibitor Mb60 + AMPPCP (3.27 Å)

**ACTIVE**
Aurora A + activator Mb54 + AMPPCP (2.06 Å)

K162
F (of DFG motif)
E181
FIG. 5
CONTINUED
FIG. 6A

FIG. 6B

$y = 0.0658x - 4E-15$
$R^2 = 0.9987$

$y = 0.0234x - 0.7548$
$R^2 = 0.9701$

$y = 0.0035x - 0.2944$
$R^2 = 0.9538$

$K_d = 9.9 \pm 2.9 \mu M$
FIG. 6C

Kd = 1.0 + 0.06 μM
4 μl Cationic liposomes
+
50nM sGFP_Mb60

FIG. 7B
FIG. 8D
FIG. 8H
**INTERNATIONAL SEARCH REPORT**

**International application No.**  PCT/US 16/15171

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(8)- C07K 17/00, C12P 2/106 (2016.01)  
CPC - C07K 14/78, C07K 16/00, C12N 15/1037, G01N 33/6845, G01N 33/573, C12N 15/1044  
According to International Patent Classification (IPC) or to both national classification and IPC

**R. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC(8)- C07K 17/00, C12P 2/106 (2016.01)  
CPC- C07K 14/78, C07K 16/00, C12N 15/1037, G01N 33/6845, G01N 33/573, C12N 15/1044

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
USPC- 530/350, 530/300, 530/324, 530/325 424/158.1, 514/215

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
PubMed(PGPB,USPT,USOC,EPAB,IPAB); PatBase, Google/Scholar: allostery site, PIF pocket, Aurora A kinase bound with TPX2, M62, Mt44, Mt51, Mt56, Mt54, and Mt60, Thr288, fluorescent sdAB, cell penetrable human monoclonal scFv, monobody, sdAB, monodies, FNII, FN3, DARPin.

GenCore 6.4.1: SEQ ID NO: 1

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>

**Further documents are listed in the continuation of Box C.**

**Date of the actual completion of the international search**  
07 June 2016 (07.06.2016)

**Date of mailing of the international search report**  
11 JUL 2016

**Name and mailing address of the ISA/US**  
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, Virginia 22313-1450

**Facsimile No.** 571-273-8300

**Authorized officer:** Lee W. Young

PCT Helpdesk: 571-272-4300  
PCT OSP: 571-272-7774

Form PCT/ISA/210 (second sheet) (January 2015)
Box No. 1  Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:

   a. ☒ forming part of the international application as filed:
      ☒ in the form of an Annex C/ST.25 text file.
      ☐ on paper or in the form of an image file.

   b. ☐ furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.

   c. ☒ furnished subsequent to the international filing date for the purposes of international search only:
      ☒ in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
      ☐ on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).

2. ☒ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

Form PCT/ISA/210 (continuation of first sheet (1)) (January 2015)
INTERNATIONAL SEARCH REPORT

Box No. II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☑ Claims Nos.: 4-10, 12, 14-18, 20-23, 27, 32-42
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

**************************************************************************************************************************** See Supplemental Sheet to continue ****************************************************************************************************************************

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☑ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-3, restricted to M12 (SEQ ID NO:1) and 1) a fragment sufficient to mediate intracellular delivery of the antibody mimetic.

Remark on Protest

☐ The additional search fees were accompanied by the applicant’s protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant’s protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2015)
In Continuation of Box III, Observations where unity of invention is lacking:

Group I: claims 1-3, directed to a fusion polypeptide comprising a first polypeptide and a second polypeptide fused to the first polypeptide, wherein the first polypeptide is an antibody mimic that specifically binds to an allosteric site of Aurora A kinase. The fusion polypeptide will be searched to the extent that the antibody mimic encompasses Mb2 (SEQ ID NO:1) and the second polypeptide encompasses i) a fragment sufficient to mediate intracellular delivery of the antibody mimic. It is believed that claims 1-3 encompass this first named invention, and thus these claims will be searched without fee to the extent that they encompass a fusion polypeptide comprising the antibody mimic encompassing Mb2 (SEQ ID NO:1) and the second polypeptide which is a fragment sufficient to mediate intracellular delivery of the antibody mimic. Additional antibody mimic(s) and the second polypeptide(s) will be searched upon the payment of additional fees. Applicants must specify the claims that encompass any additionally elected antibody mimic(s) and the second polypeptide(s). Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched. An exemplary election would be a fusion polypeptide comprising Mb4 (SEQ ID NO:2) and ii) a detectable moiety, i.e. claims 1-3.

Group II: claims 11, 13, directed to an expression vector comprising a polynucleotide encoding an antibody mimic that specifically binds to an allosteric site and a second peptide.

Group III: claims 19, 28, 31, 43, directed to a pharmaceutical composition comprising a polynucleotide encoding an antibody mimic that specifically binds to an allosteric site of Aurora A kinase (claim 19) and a method comprising contacting an Aurora A kinase in the cell with a polypeptide comprising an antibody mimic that specifically binds to an allosteric site of Aurora A kinase.

Group IV: claims 24-26, directed to a method of identifying an antibody mimic that specifically binds to an allosteric site of Aurora A kinase.

The inventions listed as Groups I, II-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features

The special technical feature of each invention of Group I is a specific monobody recited therein, because no significant structural similarities can readily be ascertained among the recited monobodies.

The special technical feature of each invention of Group I is a specific second polypeptide, because no significant structural similarities can readily be ascertained among the recited second polypeptides I-III.

The inventions of Groups I, II, and III do not include the shared or common technical feature of a method of identifying an antibody mimic that specifically binds to an allosteric site of Aurora A kinase, as required by Group IV.

The inventions of Group IV do not include the shared or common technical feature of an expression vector comprising a polynucleotide encoding an antibody mimic that specifically binds to an allosteric site of Aurora A kinase and a second peptide, as required by Group II, or a pharmaceutical composition or a method comprising contacting an Aurora A kinase in the cell with a polypeptide comprising an antibody mimic that specifically binds to an allosteric site of Aurora A kinase, as required by Group III.

The inventions of Groups I and II do not include the shared or common technical feature of a pharmaceutical composition comprising an antibody mimic that specifically binds to an allosteric site of Aurora A kinase or a method comprising contacting an Aurora A kinase in the cell with a polypeptide comprising an antibody mimic that specifically binds to an allosteric site of Aurora A kinase, as required by Group III.

The inventions of Group II do not include the shared or common technical feature of an expression vector comprising a polynucleotide encoding an antibody mimic that specifically binds to an allosteric site of Aurora A kinase and a second peptide, as required by Group II.

The inventions of Group I do not include the shared or common technical feature of an expression vector comprising a polynucleotide encoding an antibody mimic that specifically binds to an allosteric site of Aurora A kinase and a second peptide, as required by Group II.

The inventions of Group II-IV do not include the shared or common technical feature of a fusion polypeptide comprising a first polypeptide and a second polypeptide fused to the first polypeptide, wherein the first polypeptide is an antibody mimic that specifically binds to an allosteric site of Aurora A kinase, as required by Group I.

Common Technical Features

The inventions of Groups I, II-IV share the technical feature of an antibody mimic that specifically binds to an allosteric site of Aurora A kinase. The inventions of Group I share the technical feature of a fusion polypeptide comprising a first polypeptide which is an antibody mimic that specifically binds to an allosteric site of Aurora A kinase and a second peptide. However, these shared technical features do not represent a contribution over prior art as being obvious over a paper titled "Phospho-regulation of human protein kinase Aurora-A: analysis using anti-phospho-Thr288 monoclonal antibodies" by Ohashi, et al. (Oncogene 2006, 25(99):7691-7702) (hereinafter "Ohashi") in view of a paper titled "Fluorophor-linked immunosorbent assay: a time- and cost-saving method for the characterization of antibody fragments using a fusion protein of a single-chain antibody fragment and enhanced green fluorescent protein" by Oelschlaeger, et al. (Anal Biochem. 2002, 309(1):27-34) (hereinafter "Oelschlaeger") as follows:

******************************************************************* See the Following Supplemental Sheet to continue *******************************************************************
In Continuation of Box III. Observations where unity of invention is lacking and the Preceding Supplemental Sheet:

Ohashi discloses a monoclonal antibody (pg 7697, col 1, Fig 5 and its legend, anti-phospho-Thr288 Aurora-A monoclonal antibody) that binds outside of the active site of Aurora A kinase and inhibits its activity (pg 7698, Fig 6 and its legend, "(a, b) Alignment with fragments of reported phosphorylation sites within Aurora-A and Aurora-B substrates, respectively. Phosphorylated residues are highlighted in red, totally conserved arginine at P-2 position are in blue and hydrophobic residues at P+1 position are in green. (c) Residues of human Aurora-A... are implicated in recognition sites of P-2 and P+1 position of substrate... (d) Molecular surface representations of P+1 pocket of human Aurora-A (left; PDB code 1OL5)... Hydrophobic pocket of Aurora-A (Leu288, Leu293, and Leu296) that accommodates side chain of substrate P+1 residue is conserved...") and inhibits activity of Aurora A kinase (pg 7697, col 1, Fig 5 and its legend, "Exploitation of anti-phospho-Thr288 Aurora-A monoclonal antibodies... (b) Anti-phospho-Thr288 Aurora-A monoclonal antibodies dose-dependently inhibit Aurora-A kinase activity.")

Ohashi does not specifically disclose that pThr288 is an allosteric site of Aurora A kinase. However, said limitation is met by inherently present in Ohashi because, per Applicant, allosteric site is a site other than the polypeptide's active site and binding to it alters the active site, thereby altering the polypeptide's activity (instant application, pg 8, In 12-20, "By "allosteric regulation," "allosteric control," or "allosteric modulation" of polypeptide activity is meant modulation of activity of the polypeptide via binding of an effector molecule to a site other than the polypeptide's active site. Binding of the effector molecule to this site (i.e., the "allosteric site") may induce conformational changes in the polypeptide that alters the active site, thereby altering the polypeptide's activity.").

Ohashi does not specifically disclose said anti-phospho-Thr288 Aurora-A monoclonal antibody in an antibody mimetic format. Oelschlaeger provides a specific motivation to reformulate the anti-phospho Aurora A (Thr288) antibody of Ohashi into the ScFv-EGFP fusion, by disclosing a fluorophor-linked immunosorbent assay that may be performed within 1.5 h and is based on the use of the fusion of an scFv to enhanced green fluorescent protein (Abstract, "Fluorophor-linked immunosorbent assay (FLISA), for the characterization of single-chain antibody fragments (scFvs) is described. The principle of the method is the fusion of an scFv to enhanced green fluorescent protein (EGFP). The scFv domain... can be detected by measuring the fluorescence of the EGFP domain. The time-consuming binding of secondary antibodies and enzyme reaction, necessary for enzyme-linked immunosorbent assays (ELISAs) are not required. Consequently, the assay time of 1.5 h needed to complete the FLISA is much shorter than that of comparable ELISAs, which require about 5 h. This renders the FLISA suitable for applications where a short assay time is essential, such as screening of mutant libraries of scFvS in directed evolution experiments or monitoring of the amount of functionally expressed recombinant protein during production processes. In contrast to a comparable ELISA, the FLISA showed no saturation when determining the relative amount of functional scFv"). By providing a motivation to one of ordinary skill in the art to combine Ohashi with Oelschlaeger, should a speedier method of pThr288 of Aurora A kinase is desired, as suggested by Oelschlaeger (Oelschlaeger, pg 28, col 1, "fast, and cheap hapten immobilized immunoassay that is based on the fusion of EGFP to an scFv, which meets these requirements. The entire assay requires only 1.5 h and no additional costs arise for chemicals apart from those for the immobilized hapten-BSA conjugate. The scFv-EGFP fusion protein is used for the binding to the hapten and for the detection by fluorescence measurement. The suitability of the FLISA for the rapid detection of analyte is demonstrated..."). It would have been obvious to one of ordinary skill in the art to, in the course of routine experimentation and with a reasonable expectation of success, to reformulate the anti-phospho Aurora A (Thr288) antibody into the anti-phospho Aurora A (Thr288)-EGFP fusion, by following the guidance of Oelschlaeger (Oelschlaeger, pg 28, col 2). As said technical feature would have been obvious to one of ordinary skill in the art at the time of the invention, this cannot be considered special technical feature that would otherwise unify the groups.

Some inventions of Group I+ share the technical feature of a monobody. However, these shared technical features do not represent a contribution over prior art as being obvious over a paper titled "A potent and highly specific FN3 monobody inhibitor of the Ab1 SH2 domain" by Wojciak, et al. (Nat Struct Mol Biol. 2010, 17(4): 519-527) (hereinafter "Wojciak"). Wojciak discloses, in the context of studying protein interaction domains (pg 1, last para), a monobody as an alternative for multi-chain, disulfide-stabilized antibodies (pg 2, last full para, "multi-chain, disulfide-stabilized antibodies are the most common protein-based inhibitors16, but as large, multi-chain, disulfide-stabilized proteins, they are not likely to fold into the functional form in the reducing environment of the cytoplasm. An attractive alternative are engineered single domain binding proteins. One of the best established systems is based on the tenth human fibronectin type III domain (FN3), a small (10 KDa), highly stable beta-sandwich protein with surface loops tolerant to extensive mutations.17 These surface loops form a binding interface analogous to that presented by the complementarity determining regions of antibodies (Fig. 1a). FN3-based binding proteins, called "monobodies" do not contain disulphides and are thus functional in both oxidizing and reducing environments, making them amenable to in vitro and cellular studies. Moreover, because monobodies tend to recognize binding "hot spots" of the target protein, they often act as competitive inhibitors."). As said technical feature was known in the art at the time of the invention, this cannot be considered special technical feature that would otherwise unify the inventions.

Groups I+, II through IV therefore lack unity under PCT Rule 13 because they do not share a same or corresponding special technical feature.

Form PCT/ISA/210 (extra sheet) (January 2015)